Author: Editor

DCISionRT: Assessing Breast Cancer Adjuvant Endocrine Therapy After BCS Chirag Shah MD By Chirag Shah, MD So this study was an analysis of 926 patients who had undergone breast conserving surgery, with or without radiation therapy and with or without endocrine therapy. They were diagnosed with ductal carcinoma in situ and this came from four groups of patients that were put together. These patients had the DCISionRT assay run on them, and they were broken up into three groups. One was the low-risk group, which was a DCISionRT score of less than or equal to 2.8. One was the elevated…

Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute and Medical Director of the Case Comprehensive Cancer Center Clinical Research Office at Cleveland Clinic. In this audio, he speaks about the EHA 2022 abstract A Real-World Evaluation of the Association Between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera: An Analysis of Data from the REVEAL Study. Outline Back story PV is characterized by clonal hematopoiesis, which results in higher peripheral blood counts and an increased risk of thrombotic events (TEs). The standard risk model used to…

At this year’s EHA meeting, we presented an abstract from the REVEAL study. Really focusing in on thrombosis risk in patients with polycythemia vera, with respect to their blood counts outside of the adequate the REVEAL study is a very large prospective observational study of patients with polycythemia vera treated in both. Community practices as well as academic practices. And it is a cross-sectional study where we enrolled 2,500 patients, again, four observations. So, there was no therapeutic intervention there. And they were followed for a minimum of 36 months after enrollment. So, we got a pretty good broad swipe…

Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, Haematologist with clinical and research interests in multiple myeloma, in particular myeloma, lymphoma and myeloid disorders at St Vincent’s Health Melbourne  and University of Melbourne Australia. In this audio, she speaks about the EHA 2022 Abstract – Carfilzomib, Dexamethasone, And Daratumumab (Kdd) Vs Carfilzomib And Dexamethasone (Kd) In Relapsed/Refractory Multiple Myeloma (Rrmm): Frailty Subgroup Analysis Of The CANDOR Study. History Frailty scores based on age, comorbidities, and functional status can assist in identifying frail patients (pts) at risk of treatment-related toxicity or poor outcomes. An examination of carfilzomib-treated patients in the clinical trials…

The study that I will be discussing today is the frailty subgroup analysis of the CANDOR study, which is a phase 3 study comparing Daratumumab, Carfilzomib and Dexamethasone. That’s Dara KD with KD that’s Carfilzomib and Dexamethasone in patients with relapse refractory, multiple myeloma. Now in the treatment of multiple myeloma sometimes efficacious treatment can result in poor outcome. If patients are FRA and cannot tolerate treatment now we know from the phase three can or study that the triplet combination of Dara KD is effective and result in a 41% relative risk reduction in progression or death compared to…

Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute and Medical Director of the Case Comprehensive Cancer Center Clinical Research Office at Cleveland Clinic. In this audio, he speaks about the EHA 2022 abstract MOMENTUM: Phase 3 randomized study of Momelotinib (MMB) versus Danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a jak inhibitor. Outline History MMB, a new oral ACVR1/ALK2 and JAK1/2 inhibitor, demonstrated clinical activity in the SIMPLIFY trials for MF symptoms, RBC transfusion requirements (anemia), and spleen volume. Targets This pivotal…

Momelotinib Shows Promising JAK and ALK2 Inhabitation in Patients With Anemic Myelofibrosis: MOMENTUM Study It’s my pleasure today to discuss with you the results of the MOMENTUM study as presented at EHA 2022. The MOMENTUM study is an incredibly important study in the development of a drug called Momelotinib, a JAK inhibitor that differentiates itself from other inhibitors that are already approved for the treatment of patients with myelofibrosis. What Effects Did Momelotinib Have on ACVR1? A key off-target effect on a molecule called ACVR1, also known as ALK2, It does have the kind of canonical JAK inhibition of JAK2…

Professor Peter Hillmen, MD, he leads the Experimental Haematology section in LICAP and the Translational Haematology Research group. He is a Professor of Experimental Haematology and Honorary Consultant Haematologist at Leeds Teaching Hospitals NHS Trust at University of Leeds. In this audio, he speaks about the EHA 2022 Abstract – The Combination Of Ibrutinib Plus Venetoclax Results In A High Rate Of Mrd Negativity In Previously Untreated Cll: The Results Of The Planned Interim Analysis Of The Phase III Ncri FLAIR Trial. History Ibrutinib (I) and venetoclax (V) both enhance CLL outcomes. I rarely eliminates measurable residual disease (MRD), whereas…

So, I presented the interim analysis of the second part of the FLARE trial, which is a randomized phase 3 trial in previous stances, CLL patients which the total trial we recruit just under 1500 patient. What we presented here was the first interim analysis of comparison of Ibrutinib (I) and venetoclax (V) compared to Ibrutinib (I) monotherapy where half the patients had reached 2 years. That was 2,274 patients randomized. So, we analyze over five total that comparison and setting MRD. First of all, we showed that the treatment well tolerated, there were no. Significant tissues with adding the…

Dana B Cardin, MD, MSCI, Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center. In this audio, she speaks about the Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.  Backstory: Early-onset pancreatic cancer (EOPC) is uncommon. It is unknown if the incidence of EOPC is increasing or how these patients are being treated. Methodology: We used SEER 2004-2016 to conduct a retrospective population-based investigation. We looked at the annual age-adjusted incidence rate (AAIR), stage at presentation, and race/ethnicity of 7802 patients, as well as treatment patterns in 7307 patients (excluding neuroendocrine tumors) under…

Dana B Cardin, MD, MSCI, Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center. In this video, she speaks about the Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.  Observation – Origins: Early-onset pancreatic cancer (EOPC) is a rare occurrence. It is unknown whether the prevalence of EOPC is increasing or how these patients are being treated. Methodologies: We used SEER 2004-2016 to conduct a retrospective, population-based analysis. We looked examined the annual age-adjusted incidence rate (AAIR), stage at presentation, and race/ethnicity of 7802 individuals, as well as treatment patterns in 7307 patients…

Professor Georgina V. Long, MD, PhD, FRACP, Chair of Melanoma Medical Oncology &Translational Research, Translational Node, Faculty of Medicine and Health at The University of Sydney. In this audio, she speaks about the ASCO 2022 Abstract – Distant Metastasis-Free Survival With Pembrolizumab Versus Placebo As Adjuvant Therapy In Stage IIB Or IIC Melanoma: The Phase 3 KEYNOTE-716 Study. Brief Overview: Patients with surgically resected high-risk Stage II melanoma will be compared to the safety and efficacy of pembrolizumab (MK-3475) against placebo in this two-part experiment. In a double-blind design, Part 1 participants will be randomly randomized to either pembrolizumab or…

Professor Georgina V. Long, MD, PhD, FRACP, Chair of Melanoma Medical Oncology &Translational Research, Translational Node, Faculty of Medicine and Health at The University of Sydney. In this video, she speaks about the ASCO 2022 Abstract – Distant Metastasis-Free Survival With Pembrolizumab Versus Placebo As Adjuvant Therapy In Stage IIB Or IIC Melanoma: The Phase 3 KEYNOTE-716 Study. Synopsis: In this two-part trial, patients with surgically resected high-risk Stage II melanoma will be compared to the safety and efficacy of pembrolizumab (MK-3475) versus placebo. Part 1 participants will be randomly assigned to either pembrolizumab or placebo in a double-blind design…

Cynthia X. Ma, MD, Professor, Department of Medicine, Oncology Division of Medial Oncology of Washington University School of Medicine. In this audio, she speaks about the ASCO 2022 Abstract – FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data. Brief Overview: The FLEX Registry will be a large-scale population-based prospective registry. All patients with stage I to III breast cancer who have MammaPrint® and BluePrint testing on a primary breast tumor are eligible to participate in the FLEX Registry, which is designed to allow for additional study arms…

Cynthia X. Ma, MD, Professor, Department of Medicine, Oncology Division of Medial Oncology of Washington University School of Medicine. In this video, she speaks about the ASCO 2022 Abstract – FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data.   Synopsis: The FLEX Registry will be set up as a large-scale, population-based prospective registry. All patients with stage I to III breast cancer who obtain MammaPrint® and BluePrint testing on a primary breast tumor are eligible to join the FLEX Registry, which is designed to allow for additional…

Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research Program at The Ottawa Hospital. In this audio, she speaks about the ASCO 2022 Abstract –  Intratumoral (IT) INT230-6 can cause tumor necrosis In Vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study). Synopsis: This is a phase II, randomized, multi-center, parallel design, window of opportunity trial including up to 90 patients with early stage breast cancer. Patients in the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery…

Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research Program at The Ottawa Hospital. In this video, she speaks about the ASCO 2022 Abstract –  Intratumoral (IT) INT230-6 can cause tumor necrosis In Vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study). Synopsis: This is a phase II, randomized, multi-center, parallel design, window of opportunity trial including up to 90 patients with early stage breast cancer. Patients in the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery…

Charles Ricordel, MD, PhD, Thoracic Oncologist at CHU de Rennes. In this audio, he speaks about the ASCO 2022 Abstract Abstract 9039: Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with NSQ NSCLC expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). Summary: The study duration for an individual patient will begin with the signing of the informed consent and will include a screening period of up to 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days after the last administration of study drug, and at least one follow-up visit after the end-of-treatment…

CEACAM5: Safety and Efficacy Outcome in Long-term Treatment with SAR408701 in Pts with NSQ NSCLC Prof Charles Ricordel By Professor Charles Ricordel As many of you may know, antibody drug conjugates are generating a lot of hype right now in the oncology field, and RFT-Sign is a novel antibody drug conjugate that selectively targets CEACAM5. CEACAM5 (Carcinoembryonic antigen-related cell adhesion molecule 5) is a membrane protein that is usually expressed in several epithelial tumor types and might be highly expressed in approximately 25% of non-squamous non-small cell lung cancers. This compound comprises a humanized monoclonal antibody drug conjugates linked to…

Heinz-Josef Lenz, MD, is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine’s oncology division. He is the associate director of clinical research of the USC Norris Comprehensive Cancer Center, is chair of the GI Oncology Program and is the co-director of the Colorectal Center. He also serves as the scientific director of the Cancer Genetics Unit. In this Audio, he speaks about the ASCO 2022 Abstract Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405. Origins: Monoamine oxidases (MAOs), which…

Heinz-Josef Lenz, MD, is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine’s oncology division. He is the associate director of clinical research of the USC Norris Comprehensive Cancer Center, is chair of the GI Oncology Program and is the co-director of the Colorectal Center. He also serves as the scientific director of the Cancer Genetics Unit. In this video, he speaks about the ASCO 2022 Abstract Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405. Origins: Monoamine oxidases (MAOs), which…

Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator at Sarah Cannon Research Institute. In this audio, she speaks about the Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen.  Enhertu (trastuzumab deruxtecan) has been approved in the United States for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2-based regimen, either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have experienced disease recurrence during or within six months of completing therapy. AstraZeneca and…

Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator at Sarah Cannon Research Institute. In this video, she speaks about the Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen. Enhertu (trastuzumab deruxtecan) has been approved in the United States for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2-based regimen, either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have experienced disease recurrence during or within six months of completing therapy. AstraZeneca and…

Jonathan Zager, MD, Chief Academic Officer, Chair, USF Department of Oncologic Sciences at Moffitt Cancer Center. In this audio, he speaks about the ASCO 2022 Abstract – FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). Synopsis: Patients with melanoma that has progressed from the eye to the liver will be evaluated in this study: Patients in the trial will be given Melphalan/HDS treatments up to a total of six times and will be monitored until death. This study will assess the treatment’s safety and effectiveness in terms of how…

Jonathan Zager, MD, Chief Academic Officer, Chair, USF Department of Oncologic Sciences at Moffitt Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). Synopsis: Patients with melanoma that has progressed from the eye to the liver will be evaluated in this study: Patients in the trial will be given Melphalan/HDS treatments up to a total of six times and will be monitored until death. This study will assess the treatment’s safety and effectiveness in terms of how…

Thomas George, MD, FACP, Professor, MD-Hematology/Oncology from UF Health Cancer Center. In this audio, he speaks about the ASCO 2022 Abstract – NSABP FC-12: A single-arm, phase II study to evaluate treatment with gevokizumab in patients with stage II/III colon cancer who remain ctDNA+ after curative surgery and adjuvant chemotherapy. Origins: The presence of circulating tumor DNA (ctDNA) in patients (pts) after surgery indicates the presence of minimal/molecular residual disease (MRD) and a near-certain likelihood of disease recurrence. Because the likelihood of recurrence is considerable and therapeutic intervention may provide clinical benefit to patients, therapeutic techniques to treat MRD following…

Thomas George, MD, FACP, Professor, MD-Hematology/Oncology from UF Health Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – NSABP FC-12: A single-arm, phase II study to evaluate treatment with gevokizumab in patients with stage II/III colon cancer who remain ctDNA+ after curative surgery and adjuvant chemotherapy. Origins: The presence of circulating tumor DNA (ctDNA) in patients (pts) after surgery indicates the presence of minimal/molecular residual disease (MRD) and a near-certain likelihood of disease recurrence. Because the likelihood of recurrence is considerable and therapeutic intervention may provide clinical benefit to patients, therapeutic techniques to treat MRD following…

Trevor M. Feinstein, MD, Oncologist, Hematologist at Piedmont Cancer Institute. In this audio, he speaks about the ASCO 2022 Abstract – DUBLIN-3 results on quality of life (QoL) in second/third-line EGFR-wild type NSCLC patients (pts) receiving docetaxel (Doc) with or without plinabulin (Plin) using the validated EORTC QLQ C30 and QLQ LC13 questionnaires. Synopsis: Lung cancer is the biggest cause of cancer-related death globally. In 2018, there were a projected 2.09 million new cases and 1.76 million deaths worldwide, according to the World Health Organization’s Global Cancer Observatory (GLOBOCAN, 2018, Fact Sheet N039). China has a relatively high incidence and…

Plinabulin Improved OS and lower Toxicity in NSCLC EGFR Wild Type The DUBLIN-3 was a randomized phase III trial from BeyondSprings Pharmaceuticals in non-small cell lung cancer. It looked at an advanced non-small cell lung cancer, EGFR wild type. And I was looking at second and third-line treatment. Patients had to progress through at least one line of therapy, but two lines of progression were okay. And patients had to have been exposed to platinum-based therapy. The randomized clinical trial was pretty broad in that it took patients with an ECOG performance status of 2 or better, and they had…

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this audio, he speaks about the ASCO 2022 Abstract – Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo). Overview: The major goal of this study is to compare the percentage of patients with DSN =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) plus pegfilgrastim versus TAC + plinabulin/pegfilgrastim combo Severe neutropenia is…

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this video, he speaks about the ASCO 2022 Abstract – Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo). Overview: The major goal of this study is to compare the percentage of patients with DSN =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) plus pegfilgrastim versus TAC + plinabulin/pegfilgrastim combo Severe neutropenia is…

Debra A. Patt, MD, Ph.D., MBA, FASCO, is a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer and research in healthcare informatics. In this audio, she speaks about the ASCO 2022 Abstract – Analyzing patient engagement with digital health tools to facilitate equity across a large statewide community oncology practice.

Debra A. Patt, MD, Ph.D., MBA, FASCO, is a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer and research in healthcare informatics. In this video, she speaks about the ASCO 2022 Abstract – Analyzing patient engagement with digital health tools to facilitate equity across a large statewide community oncology practice.

Ping Ye, Ph.D., a senior data scientist for the U.S. Oncology Network, and McKesson. In this audio, she speaks about the ASCO 2022 Abstract – The initial outcome of deploying a mortality prediction tool at community oncology practices.

Ping Ye, Ph.D., a senior data scientist for the U.S. Oncology Network, and McKesson. In this video, she speaks about the ASCO 2022 Abstract – The initial outcome of deploying a mortality prediction tool at community oncology practices.

Mark T. Fleming, MD is a board-certified medical oncologist. He earned his B.A. from the famous University of Pennsylvania in Philadelphia and his M.D. from the Medical University of Ohio. Dr. Fleming did his residency and Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY. He later became a member of Virginia Oncology Associates (VOA). In this video, he speaks about the ASCO Abstract – The impact of diversity, equity, and inclusion training in an independent community oncology practice.

Mark T. Fleming, MD is a board-certified medical oncologist. He earned his B.A. from the famous University of Pennsylvania in Philadelphia and his M.D. from the Medical University of Ohio. Dr. Fleming did his residency and Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY. He later became a member of Virginia Oncology Associates (VOA). In this video, he speaks about the ASCO Abstract – The impact of diversity, equity, and inclusion training in an independent community oncology practice.

Audio: So I’m Dr. Gabriel Chiosis. I’m a professor and member at Sloan-Kettering Cancer Center and I’m going to discuss today our work or an overview first of our approach to treatment which is to target 1330 interaction networks rather than a protein or an interact or the interaction of two proteins as generally or at least historically we think about therapy, and the paper I was invited to discuss is it’s a protocol we published recently our cells…Read Full Transcript Here Gabriela Chiosis, Ph.D., Researcher at Memorial Sloan Kettering Cancer Center. In this video, she speaks a Gabriela Chiosis,…

Protocol Synthesis of 124I-labeled epichaperome probes and assessment in visualizing pathologic protein-protein interaction networks I’m going to discuss today our work or an overview first of our approach to treatment, which is to target 1313 interaction, rather than a protein or an Interact or interaction of 2 proteins as generally or at least historically we think about therapy. And the paper I was invited to discuss is it’s a protocol we published recently. In cancer cells SAR protocols, and it’s called Synthesis of Labeled Epichaperome Probes and assessment in visualizing pathologic protein interaction networks in tumor-bearing mice. Understanding Epichaperome Probes…

Richard Kim, MD, Professor, clinical and research interests focus on gastrointestinal tumors, in particular, hepatobiliary and colon cancer at Moffitt Cancer Center.  He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and II trials using novel targeted agents. In this video, he speaks to us about the ASCO 2022 Abstract – Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D. Overview: The goal of this study is to determine the safety and tolerability of the following combinations, as well as to establish a preliminary recommended Phase…

Richard Kim, MD, Professor, clinical and research interests focus on gastrointestinal tumors, in particular, hepatobiliary and colon cancer at Moffitt Cancer Center.  He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and II trials using novel targeted agents. In this video, he speaks to us about the ASCO 2022 Abstract – Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D. Overview: The goal of this study is to determine the safety and tolerability of the following combinations, as well as to establish a preliminary recommended Phase…

Andrea Grace Bocobo, BS, Fourth-year medical student at Touro University California and Visiting Graduate Student at UCSF GI Oncology. In this video, she speaks about the ASCO 2022 Abstract – Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Synopsis: This phase II trial investigates the side effects and optimal dose of capecitabine when combined with pembrolizumab and bevacizumab, as well as how well they work in treating patients with microsatellite stable colorectal cancer that has spread to nearby tissues or lymph nodes, has spread to other parts of the body, or…

Andrea Grace Bocobo, BS, Fourth-year medical student at Touro University California and Visiting Graduate Student at UCSF GI Oncology. In this video, she speaks about the ASCO 2022 Abstract – Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Synopsis: This phase II trial investigates the side effects and optimal dose of capecitabine when combined with pembrolizumab and bevacizumab, as well as how well they work in treating patients with microsatellite stable colorectal cancer that has spread to nearby tissues or lymph nodes, has spread to other parts of the body, or…

Abhishek Tripathi, MD, Assistant Professor of Medicine in the section of Hematology/Oncology at the University Of Oklahoma Health Sciences Center. In this video, he speaks about the ASCO 2022 Abstract – Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Overview: Reasoning: Prostate cancer cells can proliferate in response to androgens. Androgen ablation therapy has the potential to prevent the adrenal glands from producing androgens. Chemotherapy drugs, such as docetaxel, function in different ways to inhibit tumor cell growth, either by killing the cells or by…

Abhishek Tripathi, MD, Assistant Professor of Medicine in the section of Hematology/Oncology at the University Of Oklahoma Health Sciences Center. In this video, he speaks about the ASCO 2022 Abstract – Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Overview: Reasoning: Prostate cancer cells can proliferate in response to androgens. Androgen ablation therapy has the potential to prevent the adrenal glands from producing androgens. Chemotherapy drugs, such as docetaxel, function in different ways to inhibit tumor cell growth, either by killing the cells or by…

Bijal Shah, MD, MS, is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3. Synopsis: The major goals of this trial are to assess the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

Bijal Shah, MD, MS, is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3. Synopsis: The major goals of this trial are to assess the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

Robert Ferguson, Ph.D., Biobehavioral Cancer Control Program at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO 2022 Abstract – Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: A model for remote clinical trial participation. Synopsis: The overarching goal of this experiment is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT), in treating chemotherapy-related cognitive impairment in breast cancer survivors (male or female). A multi-center, multi-clinician randomized control trial is being conducted (MAAT vs. supportive therapy attention control condition). This trial will also…

Robert Ferguson, Ph.D., Biobehavioral Cancer Control Program at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO 2022 Abstract – Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: A model for remote clinical trial participation. Synopsis: The overarching goal of this experiment is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT), in treating chemotherapy-related cognitive impairment in breast cancer survivors (male or female). A multi-center, multi-clinician randomized control trial is being conducted (MAAT vs. supportive therapy attention control condition). This trial will also…

Ruben Mesa, MD, FACP, Executive Director of the Mays Cancer Center, home to UT Health San Antonio, MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. Origins: MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, shown clinical activity in the SIMPLIFY trials for MF symptoms, RBC transfusion requirements (anemia), and spleen volume. This pivotal phase 3 research compared MMB to DAN on major symptom, anemia, and spleen volume endpoints at 24…

Ruben Mesa, MD, FACP, Executive Director of the Mays Cancer Center, home to UT Health San Antonio, MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. Origins: MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, shown clinical activity in the SIMPLIFY trials for MF symptoms, RBC transfusion requirements (anemia), and spleen volume. This pivotal phase 3 research compared MMB to DAN on major symptom, anemia, and spleen volume endpoints at 24…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775 (309). Origins: In the multicenter, open-label, randomized, phase 3 Study 309/KEYNOTE-775, LEN + pembro demonstrated significant PFS and overall survival advantages, as well as a higher objective response rate compared to TPC in patients with aEC after systemic platinum-based treatment (Makker 2022,…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775 (309). Origins: In the multicenter, open-label, randomized, phase 3 Study 309/KEYNOTE-775, LEN + pembro demonstrated significant PFS and overall survival advantages, as well as a higher objective response rate compared to TPC in patients with aEC after systemic platinum-based treatment (Makker 2022,…

Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III…

Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III…

Howard M. Sandler, MD, Ronald H. Bloom Family Chair, Cancer Therapeutics, Chair, Department of Radiation Oncology, Professor, Radiation Oncology at Cedars-Sinai. In this video, he speaks about the ASCO 2022 Abstract – Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC). Origins: HRLPC is currently managed with long-term ADT and main RT. Despite receiving definitive primary care, these patients face a high risk of metastases and mortality. The phase 3 ATLAS research (NCT02531516)…

Howard M. Sandler, MD, Ronald H. Bloom Family Chair, Cancer Therapeutics, Chair, Department of Radiation Oncology, Professor, Radiation Oncology at Cedars-Sinai. In this video, he speaks about the ASCO 2022 Abstract – Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC). Origins: HRLPC is currently managed with long-term ADT and main RT. Despite receiving definitive primary care, these patients face a high risk of metastases and mortality. The phase 3 ATLAS research (NCT02531516)…

Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, William M. Scholl Professor and Vice-Chair Department of Oncology and Professor of Medicine Georgetown University Medical Center. In this video, he speaks about the ASCO 2022 Abstract – Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134). Origins: In patients with BRAFV600 mutant MM, combinations of immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) or BRAF/MEK-targeted treatments showed considerable clinical benefit. Until recently, there was little prospective evidence to advise the…

Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, William M. Scholl Professor and Vice-Chair Department of Oncology and Professor of Medicine Georgetown University Medical Center. In this video, he speaks about the ASCO 2022 Abstract – Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134). Origins: In patients with BRAFV600 mutant MM, combinations of immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) or BRAF/MEK-targeted treatments showed considerable clinical benefit. Until recently, there was little prospective evidence to advise the…

Diwakar Davar, MBBS, M.Sc, Assistant Professor, Phase I Therapeutics and Melanoma at UPMC. In this video, he speaks about the ASCO 2022 Abstract – Dose Escalation of Davoceticept, a conditional CD28 Costimulator and Dual Checkpoint Inhibitor, in Advanced Malignancies (NEON-1). Origins: Combining checkpoint inhibition (CPI) with T cell costimulatory agonists, notably CD28, a major T cell costimulatory ligand recognized as a significant target of checkpoint inhibition, has a strong preclinical rationale. Davoceticept (ALPN-202) is a PD-L1-dependent CD80 vIgD-Fc fusion that mediates CD28 costimulation and suppresses the PD-L1 and CTLA-4 checkpoints. It has outperformed CPI-only therapy in vitro and in vivo…

Diwakar Davar, MBBS, M.Sc, Assistant Professor, Phase I Therapeutics and Melanoma at UPMC. In this video, he speaks about the ASCO 2022 Abstract – Dose Escalation of Davoceticept, a conditional CD28 Costimulator and Dual Checkpoint Inhibitor, in Advanced Malignancies (NEON-1). Origins: Combining checkpoint inhibition (CPI) with T cell costimulatory agonists, notably CD28, a major T cell costimulatory ligand recognized as a significant target of checkpoint inhibition, has a strong preclinical rationale. Davoceticept (ALPN-202) is a PD-L1-dependent CD80 vIgD-Fc fusion that mediates CD28 costimulation and suppresses the PD-L1 and CTLA-4 checkpoints. It has outperformed CPI-only therapy in vitro and in vivo…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study (307). Origins: In the open-label, randomized, phase 3 CLEAR trial, LEN + PEMBRO outperformed SUN in terms of PFS (primary endpoint) and OS (key secondary endpoint) in patients with aRCC in the 1L scenario (Motzer 2021, NEJM). In the CLEAR LEN + PEMBRO and SUN treatment groups, we assessed PFS…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study (307). Origins: In the open-label, randomized, phase 3 CLEAR trial, LEN + PEMBRO outperformed SUN in terms of PFS (primary endpoint) and OS (key secondary endpoint) in patients with aRCC in the 1L scenario (Motzer 2021, NEJM). In the CLEAR LEN + PEMBRO and SUN treatment groups, we assessed PFS…

Professor Mary O’Brien, Consultant Medical Oncologist MD FRCP at The Royal Marsden NHS Foundation Trust (RHM), Professor of practice (medical oncology) from Imperial College London. In this video, she speaks about the ASCO 2022 – Discussion – EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. Origins: Pembrolizumab significantly improved DFS compared to placebo in patients (pts) with completely resected stage IB (T 4 cm) to IIIA NSCLC per AJCC v7, regardless of PD-L1 expression (N = 1177, HR…

Professor Mary O’Brien, Consultant Medical Oncologist MD FRCP at The Royal Marsden NHS Foundation Trust (RHM), Professor of practice (medical oncology) from Imperial College London. In this video, she speaks about the ASCO 2022 – Discussion – EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. Origins: Pembrolizumab significantly improved DFS compared to placebo in patients (pts) with completely resected stage IB (T 4 cm) to IIIA NSCLC per AJCC v7, regardless of PD-L1 expression (N = 1177, HR…

Steven Ansell, MD, PhD, Professor of Medicine at Mayo Clinic. In this video, he speaks about the ASCO Abstract – First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. Origins: To date, an overall survival (OS) benefit from innovative therapy combinations over conventional treatments in first-line classical Hodgkin lymphoma has seldom been demonstrated (cHL). The development of more active medicines for relapsed/refractory illness has made demonstrating increased OS with first-line therapy difficult. In ECHELON-1 (NCT01712490), 5-year follow-up studies supported the long-term progression-free survival (PFS) benefit of first-line…

The clinical trial that we are discussing is Echelon-1. This is a study specifically for patients with advanced-stage Hodgkin’s lymphoma stages 3 and 4, and it’s a study really evaluating the addition of new novel targets to frontline therapy. Brentuximab vedotin is an antibody-drug conjugate that has been very successful in patients with Hodgkin’s lymphoma in the relapse setting. And now is being tested in the frontline in comparison to ABVD chemotherapy. So, the echelon one trial compared brentuximab vedotin and ABVD chemotherapy. To a standard of care which is ABVD chemotherapy. And the key findings have been reported over…

Ian Krop, MD, Ph.D., Associate Cancer Center Director for Clinical Research; Yale Cancer Center. In this video, he speaks about the ASCO 2022 abstract – 486a – Phase 2 Trial of Tucatinib plus Trastuzumab Deruxetan in Patients with HER2+ Locally Advanced or Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB-04, trial in progress). Origins: Tucatinib is a reversible small-molecule tyrosine kinase inhibitor administered orally that is highly selective for human epidermal growth factor receptor 2. (HER2). Tucatinib is licensed in the United States for treatment in adult patients with HER2+ metastatic breast cancer (MBC), with or without brain metastases,…

Ian Krop, MD, Ph.D., Associate Cancer Center Director for Clinical Research; Yale Cancer Center. In this video, he speaks about the ASCO 2022 abstract – 486a – Phase 2 Trial of Tucatinib plus Trastuzumab Deruxetan in Patients with HER2+ Locally Advanced or Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB-04, trial in progress). Origins: Tucatinib is a reversible small-molecule tyrosine kinase inhibitor administered orally that is highly selective for human epidermal growth factor receptor 2. (HER2). Tucatinib is licensed in the United States for treatment in adult patients with HER2+ metastatic breast cancer (MBC), with or without brain metastases,…

Thomas Hope, MD, Associate Professor in Residence at UC San Francisco. In this video, he speaks about the ASCO 2022 Abstract – Imaging of solid tumors using 68Ga-FAP-2286. Origins: Fibroblast Activation Protein (FAP) is a transmembrane protein that is overexpressed on cancer-associated fibroblasts (CAFs) and is prevalent in many epithelial malignancies, implying that FAP is an appealing imaging and therapeutic target. FAP-2286 is a cyclic peptide that binds to FAP and is being tested as a radioligand therapy for patients with FAP-positive solid tumors. It is uncertain what role 68Ga-FAP-2286 plays as a diagnostic agent. We offer an interim investigation…

Thomas Hope, MD, Associate Professor in Residence at UC San Francisco. In this video, he speaks about the ASCO 2022 Abstract – Imaging of solid tumors using 68Ga-FAP-2286. Origins: Fibroblast Activation Protein (FAP) is a transmembrane protein that is overexpressed on cancer-associated fibroblasts (CAFs) and is prevalent in many epithelial malignancies, implying that FAP is an appealing imaging and therapeutic target. FAP-2286 is a cyclic peptide that binds to FAP and is being tested as a radioligand therapy for patients with FAP-positive solid tumors. It is uncertain what role 68Ga-FAP-2286 plays as a diagnostic agent. We offer an interim investigation…

Pamela Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Vice Chief, DEI, Medical Oncology at Yale University. In this video, she speaks about the ASCO 2022 Abstract – A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).   Origins: Advanced pancreatic neuroendocrine tumors (NETs) patients have few therapy choices that result in objective tumor response. According to retrospective and modest prospective studies, the combination of…

Pamela Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Vice Chief, DEI, Medical Oncology at Yale University. In this video, she speaks about the ASCO 2022 Abstract – A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).   Origins: Advanced pancreatic neuroendocrine tumors (NETs) patients have few therapy choices that result in objective tumor response. According to retrospective and modest prospective studies, the combination of…

Matthew J. Frigault, MD, Clinical Director- Cellular Immunotherapy Program at Mass General Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma. Origins: Chimeric Antigen Receptor (CAR) T cell treatments targeting B-cell maturation antigen (BCMA) have shown promise in individuals with relapsed or refractory Multiple Myeloma (RRMM). CART-ddBCMA is an autologous anti-BCMA CAR T cell treatment that employs a unique, synthetic binding domain known as a D-Domain rather than a traditional scFv binder. The goal of this first-in-human experiment is to evaluate CART-safety ddBCMA’s and efficacy.…

Matthew J. Frigault, MD, Clinical Director- Cellular Immunotherapy Program at Mass General Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma. Origins: Chimeric Antigen Receptor (CAR) T cell treatments targeting B-cell maturation antigen (BCMA) have shown promise in individuals with relapsed or refractory Multiple Myeloma (RRMM). CART-ddBCMA is an autologous anti-BCMA CAR T cell treatment that employs a unique, synthetic binding domain known as a D-Domain rather than a traditional scFv binder. The goal of this first-in-human experiment is to evaluate CART-safety ddBCMA’s and efficacy.…

Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic. In this video, he speaks about H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Relevance This study demonstrates that antiandrogen therapy produces viral mimicking reactions, which are essential for anticancer efficacy. In prostate cancer, H3K9 trimethylation to silence endogenous repeat regions is critical for restoring heterochromatin stability and progressing to antiandrogen resistance. The H3K9 trimethylation mechanism has been linked to poor outcomes in men with prostate cancer, according to our findings. Drug-resistant cancers can be resensitized and cytotoxic interferon responses elicited by blocking…

Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic. In this video, he speaks about H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Relevance This study demonstrates that antiandrogen therapy produces viral mimicking reactions, which are essential for anticancer efficacy. In prostate cancer, H3K9 trimethylation to silence endogenous repeat regions is critical for restoring heterochromatin stability and progressing to antiandrogen resistance. The H3K9 trimethylation mechanism has been linked to poor outcomes in men with prostate cancer, according to our findings. Drug-resistant cancers can be resensitized and cytotoxic interferon responses elicited by blocking…

Min Sun, MD, Ph.D., Oncologist, and Hematologist at UPMC Hillman Cancer Center, Clinical Assistant Professor at the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO Abstract – Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08. History • C-07 was a Phase III clinical trial1 that proved the efficacy of combining oxaliplatin (Oxi) with fluorouracil plus leucovorin (FULV) in adjuvant therapy for patients with stage II and III colon cancer (CC). • Oxi causes neuropathy in 90% of patients; de-escalation will…

Min Sun, MD, Ph.D., Oncologist, and Hematologist at UPMC Hillman Cancer Center, Clinical Assistant Professor at the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO Abstract – Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08. History • C-07 was a Phase III clinical trial1 that proved the efficacy of combining oxaliplatin (Oxi) with fluorouracil plus leucovorin (FULV) in adjuvant therapy for patients with stage II and III colon cancer (CC). • Oxi causes neuropathy in 90% of patients; de-escalation will…

Nageshwara Arvind Dasari, MD, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine at MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and…

Nageshwara Arvind Dasari, MD, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine at MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and…

Elyse R. Park, Ph.D., MSPH, Associate Director of the MGH Survivorship Program & I direct the MGH Medicine/Psychiatry HPRIR program, Harvard Medical School at Harvard University. In this video, she speaks about the ASCO 2022 Abstract – A health insurance navigation intervention tool (HINT) for survivors of childhood cancer: Randomized pilot trial results from the Childhood Cancer Survivor Study. Summary: The Childhood Cancer Survivor Study (CCSS) will look into the long-term impact of cancer and its treatments. A multi-institutional partnership will perform a retrospective cohort study that will involve the identification and active follow-up of roughly 50,000 cancer survivors diagnosed…

Elyse R. Park, Ph.D., MSPH, Associate Director of the MGH Survivorship Program & I direct the MGH Medicine/Psychiatry HPRIR program, Harvard Medical School at Harvard University. In this video, she speaks about the ASCO 2022 Abstract – A health insurance navigation intervention tool (HINT) for survivors of childhood cancer: Randomized pilot trial results from the Childhood Cancer Survivor Study. Summary: The Childhood Cancer Survivor Study (CCSS) will look into the long-term impact of cancer and its treatments. A multi-institutional partnership will perform a retrospective cohort study that will involve the identification and active follow-up of roughly 50,000 cancer survivors diagnosed…

Sue S. Yom, MD, Ph.D., Professor and Vice Chair, Strategic AdvisoryDepartment of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgery at University of California San Francisco. In this video, she speaks about the Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.  Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for…

Sue S. Yom, MD, Ph.D., Professor and Vice Chair, Strategic AdvisoryDepartment of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgery at University of California San Francisco. In this video, she speaks about the Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.  Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for…

Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO 2022 Abstract Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. Origins: The first positive phase 3 study of adjuvant immunotherapy for patients (pts) with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions is the double-blind, multicenter, randomized KEYNOTE-564 study (NCT03142334).…

Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO 2022 Abstract Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. Origins: The first positive phase 3 study of adjuvant immunotherapy for patients (pts) with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions is the double-blind, multicenter, randomized KEYNOTE-564 study (NCT03142334).…

Roger Li, MD, Genitourinary Oncologist at Moffitt Cancer Center. In this video, he speaks about ASCO 2022 abstract CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG). Origins: CG0070 is an oncolytic vaccine based on Ad5 that has been modified to express GM-CSF and replicate selectively in tumor cells with mutant or defective RB. The mechanism of action of CG0070 comprises cell lysis and immunogenic cell death, which is accelerated in the presence of GM-CSF. In an open label phase 2 research, individuals with high risk NMIBC…

Roger Li, MD, Genitourinary Oncologist at Moffitt Cancer Center. In this video, he speaks about ASCO 2022 abstract CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG). Origins: CG0070 is an oncolytic vaccine based on Ad5 that has been modified to express GM-CSF and replicate selectively in tumor cells with mutant or defective RB. The mechanism of action of CG0070 comprises cell lysis and immunogenic cell death, which is accelerated in the presence of GM-CSF. In an open label phase 2 research, individuals with high risk NMIBC…

Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. In this video, she speaks about the ASCO 2022 Abstract – Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. Origins: Ide-cel, a BCMA-directed CAR T-cell therapy, was approved by the FDA on March 26, 2021, for the treatment of RRMM after four prior lines of therapy. We looked at the real-world outcomes of patients who received standard-of-care ide-cel under a commercial FDA label. Methodology: Independent of the company, ten…

Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. In this video, she speaks about the ASCO 2022 Abstract – Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. Origins: Ide-cel, a BCMA-directed CAR T-cell therapy, was approved by the FDA on March 26, 2021, for the treatment of RRMM after four prior lines of therapy. We looked at the real-world outcomes of patients who received standard-of-care ide-cel under a commercial FDA label. Methodology: Independent of the company, ten…

Michael Cecchini, MD, Assistant Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers at Yale University. In this video, he speaks about the ASCO 2022 Abstract – Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.

Michael Cecchini, MD, Assistant Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers at Yale University. In this video, he speaks about the ASCO 2022 Abstract – Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about the ASCO 2022 Late-Breaking Abstract – Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.  Origins: Most…

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about the ASCO 2022 Late-Breaking Abstract – Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.  Origins: Most…

Sumanta (Monty) Pal, MD, FASCO, Professor, Department of Medical Oncology & Therapeutics Research and Co-director, Kidney Cancer Program at City of Hope. In this video, he speaks about ASCO 2022 Abstract – Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study. Origins: C, a multitargeted receptor tyrosine kinase inhibitor (TKI), provides an immunological-permissive milieu that may boost immune checkpoint inhibitor responsiveness (ICIs). COSMIC-021, a multicenter phase 1b trial, is looking into C + A (anti-PD-L1 treatment) in a variety of solid tumors (NCT03170960). C + A indicated promising…

Sumanta (Monty) Pal, MD, FASCO, Professor, Department of Medical Oncology & Therapeutics Research and Co-director, Kidney Cancer Program at City of Hope. In this video, he speaks about ASCO 2022 Abstract – Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study. Origins: C, a multitargeted receptor tyrosine kinase inhibitor (TKI), provides an immunological-permissive milieu that may boost immune checkpoint inhibitor responsiveness (ICIs). COSMIC-021, a multicenter phase 1b trial, is looking into C + A (anti-PD-L1 treatment) in a variety of solid tumors (NCT03170960). C + A indicated promising…

Karim Chamie, MD, Associate Professor of Urology and Society of Urologic Oncology Fellowship Director at UCLA Health. In this video, he speaks about the ASCO 2022 Abstract – Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). Origins: Patients with NMIBC CIS who are not responding to BCG have few therapeutic choices. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL15RaFc) that increases natural killer (NK) cell proliferation and activation but not regulatory T cell activation. In BCG-naive patients with NMIBC, phase 1b findings show that…

Karim Chamie, MD, Associate Professor of Urology and Society of Urologic Oncology Fellowship Director at UCLA Health. In this video, he speaks about the ASCO 2022 Abstract – Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). Origins: Patients with NMIBC CIS who are not responding to BCG have few therapeutic choices. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL15RaFc) that increases natural killer (NK) cell proliferation and activation but not regulatory T cell activation. In BCG-naive patients with NMIBC, phase 1b findings show that…

Clinical Data Management Tools Enables Flexibility and ScalabilitySupporting Evolving Oncology Clinical Study Designs   OncologyTube was privileged to feature Mike Keens, Executive Vice President, Anju Software (https://www.anjusoftware.com), and Stefan Michiels, Head of Department of Biostatistics and Epidemiology, Gustave Roussy (https://www.gustaveroussy.fr/en).  These gentlemen discussed key aspects of oncology clinical trial enrollment challenges and solutions, especially during and post COVID-19 pandemic.   At the outset of COVID-19 during the first quarter of 2020, enrollment within most clinical trials stopped – apart from COVID-19 vaccine trials.  Between March 2020 and May 2020, all ongoing trials scrambled to continue visits at home or attempted…

Aaron Logan, MD, Ph.D., Hematologist, Associate Professor of Clinical Medicine at UC San Francisco. In this video, he speaks about The Treatment Landscape Of ALL. A form of blood and bone marrow malignancy that affects white blood cells. The most frequent type of juvenile cancer is acute lymphoblastic leukemia. It happens when a bone marrow cell’s DNA becomes faulty. Enlarged lymph nodes, bruising, fever, bone discomfort, gum bleeding, and repeated infections are all possible symptoms. Chemotherapy or targeted medications that precisely kill cancer cells may be used as treatments.

Aaron Logan, MD, Ph.D., Hematologist, Associate Professor of Clinical Medicine at UC San Francisco. In this video, he speaks about The Treatment Landscape Of ALL.   A form of blood and bone marrow malignancy that affects white blood cells. The most frequent type of juvenile cancer is acute lymphoblastic leukemia. It happens when a bone marrow cell’s DNA becomes faulty. Enlarged lymph nodes, bruising, fever, bone discomfort, gum bleeding, and repeated infections are all possible symptoms. Chemotherapy or targeted medications that precisely kill cancer cells may be used as treatments.

Spyridon Basourakos, MD, Urology Resident 5th year at Weill Cornell Medicine, Jonathan E. Shoag, MD, Adjunct Clinical Assistant Professor of Urology Weill Cornell Medicine Assistant Professor Casewestern and Yaw Nyame, MD, MS, MBA, Assistant Professor, Surgeon, Researcher at the University of Washington. In this video, they discuss the AUA 2022 abstract – LBA01-01: Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.   Details   Spyridon Basourakos, Roman Gulati, Randy Vince, Daniel Spratt, Patrick Lewicki, Alexander Hill, Yaw Nyame, Jennifer Cullen, Sarah Markt, Christopher Barbieri, Jim Hu, and Jonathan Shoag are among the authors.   Intro:   Prostate-specific…

Spyridon Basourakos, MD, Urology Resident 5th year at Weill Cornell Medicine, Jonathan E. Shoag, MD, Adjunct Clinical Assistant Professor of Urology Weill Cornell Medicine Assistant Professor Casewestern and Yaw Nyame, MD, MS, MBA, Assistant Professor, Surgeon, Researcher at the University of Washington. In this video, they discuss the AUA 2022 abstract – LBA01-01: Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.   Details   Spyridon Basourakos, Roman Gulati, Randy Vince, Daniel Spratt, Patrick Lewicki, Alexander Hill, Yaw Nyame, Jennifer Cullen, Sarah Markt, Christopher Barbieri, Jim Hu, and Jonathan Shoag are among the authors.   Intro:   Prostate-specific…

Neeraj Agarwal, MD, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI. In this video, he speaks about Prostate Cancer OS Is Up Significantly.   Observation –   Intention:   Orteronel (TAK-700) is a nonsteroidal androgen-suppressing 17,20-lyase inhibitor. We looked at how orteronel performed when combined with androgen deprivation therapy (ADT) in individuals with newly diagnosed metastatic hormone-sensitive prostate cancer.   Methodology:   Patients with metastatic hormone-sensitive prostate cancer were randomly…

Neeraj Agarwal, MD, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI. In this video, he speaks about Prostate Cancer OS Is Up Significantly.   Observation –   Intention:   Orteronel (TAK-700) is a nonsteroidal androgen-suppressing 17,20-lyase inhibitor. We looked at how orteronel performed when combined with androgen deprivation therapy (ADT) in individuals with newly diagnosed metastatic hormone-sensitive prostate cancer.   Methodology:   Patients with metastatic hormone-sensitive prostate cancer were randomly…

EXUMA Biotech’s VP of Oncology R&D, Dr. Sid Kerkar, Reveals Preclinical Data From Its Subcutaneous CAR-TaNK And In Vivo CAR Cell And Gene Therapy Programs  EXUMA Biotech, Corp., is a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors.  EXUMA is currently conducting IND-enabling studies of the first products on its CAR-TaNK cell therapy platform, targeting CD19 and CD22. CAR-TaNKs are potent cancer killers with T and NK features, which preclinically have been observed to reproducibly and robustly expand in vivo in lymphoreplete animal models following the generation of synthetic lymph nodes post subcutaneous injection. Based…

Maria Soledad Sosa, Ph.D.,  Assistant Professor of Pharmacological Sciences, and Oncological Sciences, at The Tisch Cancer Institute at Mount Sinai. In this video, she speaks about the Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients.   Mount Sinai researchers have found a previously unknown process by which non-malignant cells from early breast cancer tumors migrate to other organs before “turning on” and becoming metastatic breast cancer.   The researchers also demonstrated the ability of the transcription factor NR2F1, a protein that controls a gene’s outward expression, to prevent pre-malignant cells from spreading,…

Maria Soledad Sosa, Ph.D.,  Assistant Professor of Pharmacological Sciences, and Oncological Sciences, at The Tisch Cancer Institute at Mount Sinai. In this video, she speaks about the Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients.   Mount Sinai researchers have found a previously unknown process by which non-malignant cells from early breast cancer tumors migrate to other organs before “turning on” and becoming metastatic breast cancer.   The researchers also demonstrated the ability of the transcription factor NR2F1, a protein that controls a gene’s outward expression, to prevent pre-malignant cells from spreading,…

Dennis J. Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center. In this video, he speaks about the New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients.   Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with advanced or metastatic breast cancer that is hormone receptor-positive but not human epidermal growth factor receptor-2 negative (HR+/HER2-). The examination of patients treated in first-line with Kisqali + fulvestrant revealed an…

Dennis J. Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center. In this video, he speaks about the New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients.   Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with advanced or metastatic breast cancer that is hormone receptor-positive but not human epidermal growth factor receptor-2 negative (HR+/HER2-). The examination of patients treated in first-line with Kisqali + fulvestrant revealed an…

Roy S. Herbst, MD, Ph.D., Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer.   Summary:   COAST is a Phase 2 open-label, multicenter, randomized multidrug platform research comparing the effectiveness and safety of durvalumab alone with durvalumab in combination with…

Roy S. Herbst, MD, Ph.D., Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer.   Summary:   COAST is a Phase 2 open-label, multicenter, randomized multidrug platform research comparing the effectiveness and safety of durvalumab alone with durvalumab in combination with…

James Yarmolinsky, Ph.D., Research Fellow at the University of Bristol. In this video, he speaks about Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.   Observation –   Origins:   In high-income countries, endometrial cancer is the most frequent gynaecological malignancy. Elevated BMI is a known modifiable risk factor for this condition, and it is thought to have a greater impact on endometrial cancer risk than any other cancer site. The molecular processes behind this relationship, however, remain unknown. Mendelian randomization (MR) was utilized to investigate the involvement of 14…

James Yarmolinsky, Ph.D., Research Fellow at the University of Bristol. In this video, he speaks about Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.   Observation –   Origins:   In high-income countries, endometrial cancer is the most frequent gynaecological malignancy. Elevated BMI is a known modifiable risk factor for this condition, and it is thought to have a greater impact on endometrial cancer risk than any other cancer site. The molecular processes behind this relationship, however, remain unknown. Mendelian randomization (MR) was utilized to investigate the involvement of 14…

Raja M. Flores, MD, Professor and System Chair, Thoracic Surgery at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the Menthol Cigarette Ban.The US Food and Drug Administration announced today proposed product guidelines that would restrict menthol as a defining taste in cigarettes and all characterizing flavors (other than tobacco) in cigars. By reducing juvenile experimentation and addiction and increasing the number of smokers who quit, these initiatives have the potential to considerably reduce disease and death from combusted tobacco product use, the main cause of preventable death in the United States.These proposed product standards…

Raja M. Flores, MD, Professor and System Chair, Thoracic Surgery at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the Menthol Cigarette Ban.The US Food and Drug Administration announced today proposed product guidelines that would restrict menthol as a defining taste in cigarettes and all characterizing flavors (other than tobacco) in cigars. By reducing juvenile experimentation and addiction and increasing the number of smokers who quit, these initiatives have the potential to considerably reduce disease and death from combusted tobacco product use, the main cause of preventable death in the United States.These proposed product standards…

Cansu Cimen Bozkus, PhD, Assistant Professor at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 abstract – 253 / 19 – Analyses of tumor-specific T cell dynamics and tumor immune contexture in microsatellite instability-high cancers in response to first-line therapy.Overview:The MSI-H phenotype is caused by faulty DNA repair processes and is present in many cancers, including colorectal and endometrial cancers. MSI-H malignancies can be used to research the aspects of neoantigen-induced anti-tumor immunity in response to therapy and disease outcome due to large neoantigen loads produced from tumor-specific mutations, evidence of tumor-infiltrating…

Cansu Cimen Bozkus, PhD, Assistant Professor at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 abstract – 253 / 19 – Analyses of tumor-specific T cell dynamics and tumor immune contexture in microsatellite instability-high cancers in response to first-line therapy.Overview:The MSI-H phenotype is caused by faulty DNA repair processes and is present in many cancers, including colorectal and endometrial cancers. MSI-H malignancies can be used to research the aspects of neoantigen-induced anti-tumor immunity in response to therapy and disease outcome due to large neoantigen loads produced from tumor-specific mutations, evidence of tumor-infiltrating…

Zeina Nahleh, MD, FACP, Cancer Center Director and Department Chair, Hematology-Oncology at the Cleveland Clinic. In this video, she speaks about The Use of Biosimilars in Oncology.   Outline   PURPOSE:    The rising quantity and use of biosimilars raises fundamental questions about their safe and acceptable use in cancer therapy. This paper gives an update on recently licensed oncology biosimilars as well as outlines existing knowledge gaps in cancer patient treatment.   Methodology:   An Expert Panel was formed to assess the medical literature and provide a practical summary of currently approved biosimilar therapies in the United States for…

Zeina Nahleh, MD, FACP, Cancer Center Director and Department Chair, Hematology-Oncology at the Cleveland Clinic. In this video, she speaks about The Use of Biosimilars in Oncology.   Outline   PURPOSE:   The rising quantity and use of biosimilars raises fundamental questions about their safe and acceptable use in cancer therapy. This paper gives an update on recently licensed oncology biosimilars as well as outlines existing knowledge gaps in cancer patient treatment.   Methodology:   An Expert Panel was formed to assess the medical literature and provide a practical summary of currently approved biosimilar therapies in the United States for…

Nichole James, Ph.D., Assistant Professor of Obstetrics and Gynecology (Research) at Brown University and Women and Infants Hospital. In this video, she speaks about the abstract Prognostic immunologic signatures in epithelial ovarian cancer.   Abstract:   Epithelial Ovarian Cancer (EOC) is a lethal gynecologic cancer that usually recurs after initial platinum-taxane chemotherapy. EOC clinical studies, like those for many other cancer subtypes, have focused on immunotherapeutic methods, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies have been modest in EOC patients, data suggests that ovarian cancers are immunogenic and that immune-related genetic profiles can…

Nichole James, Ph.D., Assistant Professor of Obstetrics and Gynecology (Research) at Brown University and Women and Infants Hospital. In this video, she speaks about the abstract Prognostic immunologic signatures in epithelial ovarian cancer.   Abstract:   Epithelial Ovarian Cancer (EOC) is a lethal gynecologic cancer that usually recurs after initial platinum-taxane chemotherapy. EOC clinical studies, like those for many other cancer subtypes, have focused on immunotherapeutic methods, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies have been modest in EOC patients, data suggests that ovarian cancers are immunogenic and that immune-related genetic profiles can…

Lajos Pusztai, MD, DPhil, Professor of Medicine, Co-Leader Genetics, Genomics, and Epigenetics Program, Scientific Co-Director of the Center for Breast Cancer, Yale Cancer Center. In this video, he speaks about the Cancer Relevance of Human Genes.   Observation –   Origins:   We postulate that genes that interact with core cancer genes (CCG) directly or indirectly in a comprehensive gene-gene interaction network may have functional value in cancer.   Methodologies:   We classified 12,767 human genes into CCGs (n = 468), one (n = 5,467), two (n = 5,573), three (n = 915), and more than three (n = 416)…

Lajos Pusztai, MD, DPhil, Professor of Medicine, Co-Leader Genetics, Genomics, and Epigenetics Program, Scientific Co-Director of the Center for Breast Cancer, Yale Cancer Center. In this video, he speaks about the Cancer Relevance of Human Genes.   Observation –   Origins:   We postulate that genes that interact with core cancer genes (CCG) directly or indirectly in a comprehensive gene-gene interaction network may have functional value in cancer.   Methodologies:   We classified 12,767 human genes into CCGs (n = 468), one (n = 5,467), two (n = 5,573), three (n = 915), and more than three (n = 416)…

Sanika Bodas, Ph.D., Ph.D. Student at University of Nebraska Medical Center. In this video, she speaks about the AACR 2022 Abstract – LB035 / 7 – Understanding the mechanism of neuropilin2 upregulation in advanced prostate cancer.   Observation –   Origins:   Androgen Deprivation Therapy (ADT) is used to treat prostate cancer (ADT). Patients with advanced prostate cancer develop resistance to ADT and progress to a fatal phenotype known as Castration Resistant Prostate Cancer (CRPC). Neuropilin-2 expression is increased in advanced prostate cancer. It has been linked to a decrease in overall survival in these individuals by generating therapeutic resistance.…

Sanika Bodas, Ph.D., Ph.D. Student at University of Nebraska Medical Center. In this video, she speaks about the AACR 2022 Abstract – LB035 / 7 – Understanding the mechanism of neuropilin2 upregulation in advanced prostate cancer.   Observation –   Origins:   Androgen Deprivation Therapy (ADT) is used to treat prostate cancer (ADT). Patients with advanced prostate cancer develop resistance to ADT and progress to a fatal phenotype known as Castration Resistant Prostate Cancer (CRPC). Neuropilin-2 expression is increased in advanced prostate cancer. It has been linked to a decrease in overall survival in these individuals by generating therapeutic resistance.…

Claire Rosean, Ph.D., Senior Scientist at Immunomic Therapeutics. In this video, she speaks about the AACR 2022 Abstract – 2052 / 10 – ITI-3000 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses, tumor inhibition, and provides rationale for first-in-human trial.   Overview:   The majority of Merkel cell carcinomas (MCC), a rare and deadly type of neuroendocrine skin cancer, are caused by Merkel cell polyomavirus (MCPyV). MCPyV integrates into the host genome, causing infected cells to express a shortened form of the viral large T antigen (LT), making LT an appealing target…

Claire Rosean, Ph.D., Senior Scientist at Immunomic Therapeutics. In this video, she speaks about the AACR 2022 Abstract – 2052 / 10 – ITI-3000 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses, tumor inhibition, and provides rationale for first-in-human trial.   Overview: The majority of Merkel cell carcinomas (MCC), a rare and deadly type of neuroendocrine skin cancer, are caused by Merkel cell polyomavirus (MCPyV). MCPyV integrates into the host genome, causing infected cells to express a shortened form of the viral large T antigen (LT), making LT an appealing target for…

Linda Kachuri, PhD, Postdoctoral Scholar, Epidemiology & Biostatistics at UC San Francisco. In this video, she speaks about the AACR 2022 Abstract – 1441 / 8 – Genetic determinants of PSA levels improve prostate cancer screening.   Overview:   PSA screening for prostate cancer (PCa) remains contentious due to low sensitivity and specificity, which leads to overdiagnosis and overtreatment. Our study’s goal is to identify genetic drivers of PSA levels in cancer-free men in order to tailor PCa screening. We expect that accounting for PSA variance that is related to genetic factors and does not reflect PCa will enhance test…

Linda Kachuri, PhD, Postdoctoral Scholar, Epidemiology & Biostatistics at UC San Francisco. In this video, she speaks about the AACR 2022 Abstract – 1441 / 8 – Genetic determinants of PSA levels improve prostate cancer screening.   Overview:   PSA screening for prostate cancer (PCa) remains contentious due to low sensitivity and specificity, which leads to overdiagnosis and overtreatment. Our study’s goal is to identify genetic drivers of PSA levels in cancer-free men in order to tailor PCa screening. We expect that accounting for PSA variance that is related to genetic factors and does not reflect PCa will enhance test…

This series offers two interactive programs supported by audio and video commentary, where Dr. Justin Gainor and Dr. Maria Arcila share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:   • Increase implementation of best practices for EGFR mutation testing in patients with NSCLC • Apply clinical trial data to treatment selection in patients with EGFR-mutant NSCLC • Understand the role of concurrent mutations, such as TP53, in the prognosis and response to therapy of patients with EGFR-mutant NSCLC   To learn more and participate in the activities,…

This series offers two interactive programs supported by audio and video commentary, where Dr. Justin Gainor and Dr. Maria Arcila share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:   • Increase implementation of best practices for EGFR mutation testing in patients with NSCLC • Apply clinical trial data to treatment selection in patients with EGFR-mutant NSCLC • Understand the role of concurrent mutations, such as TP53, in the prognosis and response to therapy of patients with EGFR-mutant NSCLC   To learn more and participate in the activities,…

Mindie H. Nguyen, MD, MAS, Fellow AGAF, Fellow FAASLD, Hepatologist, Transplant hepatologist, Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health at Stanford Health Care. In this video, she speaks about the Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer.   The goal of this study is to define the performance characteristics (sensitivity and specificity) of the Helio Liver Test in a study population of subjects with liver cancer at various stages (I to IV) and for control subjects who have been…

Mindie H. Nguyen, MD, MAS, Fellow AGAF, Fellow FAASLD, Hepatologist, Transplant hepatologist, Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health at Stanford Health Care. In this video, she speaks about the Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer.   The goal of this study is to define the performance characteristics (sensitivity and specificity) of the Helio Liver Test in a study population of subjects with liver cancer at various stages (I to IV) and for control subjects who have been…

Federico Aucejo, MD, is the Director of the Liver Cancer Program and Surgical Director of the Liver Tumor Clinic in the Department of General Surgery at Cleveland Clinic’s main campus.. In this video,  he speaks about the article Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases.   Question on Key Points What are the estimated overall and recurrence-free survival outcomes following living-donor liver transplantation (LDLT) in patients with liver-confined, unresectable colorectal cancer liver metastases (CRLM)?   Conclusions: At a median follow-up of 1.5 years, Kaplan-Meier estimates of recurrence-free and overall survival in this cohort analysis…

Federico Aucejo, MD, is the Director of the Liver Cancer Program and Surgical Director of the Liver Tumor Clinic in the Department of General Surgery at Cleveland Clinic’s main campus.. In this video,  he speaks about the article Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases.   Question on Key Points What are the estimated overall and recurrence-free survival outcomes following living-donor liver transplantation (LDLT) in patients with liver-confined, unresectable colorectal cancer liver metastases (CRLM)?   Conclusions: At a median follow-up of 1.5 years, Kaplan-Meier estimates of recurrence-free and overall survival in this cohort analysis…

Alberto Anel, Ph.D., Professor of Biochemistry, Department of Biochemistry and Molecular and Cellular Biology, Biochemistry and Molecular Biology Area, Science Faculty at the Universidad De Zaragoza. In this video, he speaks about the AACR 2022 Abstract – Mechanistic Insights On PT-112’s Effects On Prostate Cancer Cell Lines.   Overview:   To test PT-112 in a human prostate cancer cell panel for differential sensitivity, cell death mechanism, development of mitochondrial stress, and release of damage-associated molecular patterns (DAMPs).   Origins:   PT-112 is a new pyrophosphate-platinum compound that has shown therapeutic effectiveness in advanced solid cancers such as lung, thymoma, and…

Alberto Anel, Ph.D., Professor of Biochemistry, Department of Biochemistry and Molecular and Cellular Biology, Biochemistry and Molecular Biology Area, Science Faculty at the Universidad De Zaragoza. In this video, he speaks about the AACR 2022 Abstract – Mechanistic Insights On PT-112’s Effects On Prostate Cancer Cell Lines. Overview: To test PT-112 in a human prostate cancer cell panel for differential sensitivity, cell death mechanism, development of mitochondrial stress, and release of damage-associated molecular patterns (DAMPs). Origins:   PT-112 is a new pyrophosphate-platinum compound that has shown therapeutic effectiveness in advanced solid cancers such as lung, thymoma, and castration-resistant PC, as…

Umamaheswar Duvvuri, MD, Ph.D., FACS, Professor, Department of Otolaryngology at UPMC and the VA Pittsburg Health System. In this video, he speaks about the article Malaria drug could help treat chemotherapy-resistant head and neck cancers.   According to a new study, the malaria medicine hydroxychloroquine blocks mechanisms that develop resistance to the chemotherapeutic agent cisplatin in head and neck tumors and restores cisplatin’s tumor-killing properties in animal models.   The findings, reported today in the Proceedings of the National Academy of Sciences by scientists from the University of Pittsburgh and UPMC, clear the way for a clinical study combining cisplatin…

Umamaheswar Duvvuri, MD, Ph.D., FACS, Professor, Department of Otolaryngology at UPMC and the VA Pittsburg Health System. In this video, he speaks about the article Malaria drug could help treat chemotherapy-resistant head and neck cancers.   According to a new study, the malaria medicine hydroxychloroquine blocks mechanisms that develop resistance to the chemotherapeutic agent cisplatin in head and neck tumors and restores cisplatin’s tumor-killing properties in animal models.   The findings, reported today in the Proceedings of the National Academy of Sciences by scientists from the University of Pittsburgh and UPMC, clear the way for a clinical study combining cisplatin…

Sarbajit Mukherjee, MD, MS, Assistant Professor, Gastrointestinal Medical Oncologist at Roswell Park Cancer Institute. In this video, he speaks about the AACR 2022 Abstract – CT105 / 2 – Initial results of a phase II study evaluating a chemokine-modulatory (CKM) regimen in patients with colorectal cancer metastatic to the liver.   Abstract   Origins:   Liver metastases occur in 20-50 percent of colorectal cancer (CRC) patients, are resistant to immune checkpoint inhibitors (ICIs), and have a poor prognosis. Our preliminary findings demonstrated a synergistic effect of IFN and TLR3 ligands in selectively increasing the intratumoral production of CD8+ T cell…

Sarbajit Mukherjee, MD, MS, Assistant Professor, Gastrointestinal Medical Oncologist at Roswell Park Cancer Institute. In this video, he speaks about the AACR 2022 Abstract – CT105 / 2 – Initial results of a phase II study evaluating a chemokine-modulatory (CKM) regimen in patients with colorectal cancer metastatic to the liver.   Abstract   Origins:   Liver metastases occur in 20-50 percent of colorectal cancer (CRC) patients, are resistant to immune checkpoint inhibitors (ICIs), and have a poor prognosis. Our preliminary findings demonstrated a synergistic effect of IFN and TLR3 ligands in selectively increasing the intratumoral production of CD8+ T cell…

Christiane Querfeld, M.D., Ph.D., Director, Cutaneous Lymphoma Program, City of Hope. In this video, she speaks about the AACR 2022 Abstract – 5196 – CD47 Blockade potentiates immunotherapy of durvalumab against cutaneous T cell lymphoma.   View Immune checkpoint (IC) inhibition for PD1 and PD-Ligand 1 (PD-L1) has shown promising and long-term therapeutic effects in cutaneous T-cell lymphoma (CTCL), but resistance and/or relapses are prevalent. While most research has focused on increasing adaptive immune functions in CTCL, we looked into the role of 1) the “don’t eat me signal” (CD47) and PD-L1 as a dual (innate and adaptive IC)-targeting strategy…

Christiane Querfeld, M.D., Ph.D., Director, Cutaneous Lymphoma Program, City of Hope. In this video, she speaks about the AACR 2022 Abstract – 5196 – CD47 Blockade potentiates immunotherapy of durvalumab against cutaneous T cell lymphoma.   View   Immune checkpoint (IC) inhibition for PD1 and PD-Ligand 1 (PD-L1) has shown promising and long-term therapeutic effects in cutaneous T-cell lymphoma (CTCL), but resistance and/or relapses are prevalent. While most research has focused on increasing adaptive immune functions in CTCL, we looked into the role of 1) the “don’t eat me signal” (CD47) and PD-L1 as a dual (innate and adaptive IC)-targeting…

Tyler Nielsen, MBioMed, Staff Scientist at Oncocyte Corporation. In this video, he speaks about the AACR 22 Abstract – 1272 / 19 – Confirmatory study of the IO Score, a tumor immune microenvironment (TIME) classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer (mUC) patients treated with immune checkpoint inhibitors (ICIs).   Outline   Origins:   Patients with mUC have a terrible prognosis, with less than 10% surviving two years following diagnosis. Because the majority of mUC patients do not survive to a second line of therapy, optimizing first-line therapy is crucial, particularly with recently approved non-ICI therapies.…

Tyler Nielsen, MBioMed, Staff Scientist at Oncocyte Corporation. In this video, he speaks about the AACR 22 Abstract – 1272 / 19 – Confirmatory study of the IO Score, a tumor immune microenvironment (TIME) classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer (mUC) patients treated with immune checkpoint inhibitors (ICIs).   Outline   Origins:   Patients with mUC have a terrible prognosis, with less than 10% surviving two years following diagnosis. Because the majority of mUC patients do not survive to a second line of therapy, optimizing first-line therapy is crucial, particularly with recently approved non-ICI therapies.…

Laura Alder, MD, Hematology-Oncology Fellow at Duke University Health System. In this video, she speaks about the AACR 2022 Abstract 5257 – Durable clinical and radiographic responses in a series of patients with HER2+ Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd). Outline   Origins:   LMD is a catastrophic clinical consequence of metastatic breast cancer, with a 4.4-month median survival for the HER2+ subtype. There are few effective LMD therapies. T-DXd shown excellent extracranial effectiveness in the DESTINY-Breast01/03 trials for metastatic HER2+ breast cancer, including stable brain metastases (BrM) subgroups. T-effectiveness DXd’s in HER2+ untreated BrM…

Laura Alder, MD, Hematology-Oncology Fellow at Duke University Health System. In this video, she speaks about the AACR 2022 Abstract 5257 – Durable clinical and radiographic responses in a series of patients with HER2+ Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd). Outline   Origins:   LMD is a catastrophic clinical consequence of metastatic breast cancer, with a 4.4-month median survival for the HER2+ subtype. There are few effective LMD therapies. T-DXd shown excellent extracranial effectiveness in the DESTINY-Breast01/03 trials for metastatic HER2+ breast cancer, including stable brain metastases (BrM) subgroups. T-effectiveness DXd’s in HER2+ untreated BrM…

Michael J. Donovan, MD, Ph.D., Research Professor of Pathology, Molecular, and Cell-Based Medicine at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – 4145 / 8 – Novel approach that combines an automated breast cancer grading platform with genomics to personalize risk assessment and management. Observation – Origins: The use of histology in determining breast cancer (BCA) clinical risk assignment, including stage, tumor size, and histologic grade, remains an important component of treatment selection and management. Recent studies have shown the value of combining these characteristics with genetic signals such as…

Michael J. Donovan, MD, Ph.D., Research Professor of Pathology, Molecular, and Cell-Based Medicine at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – 4145 / 8 – Novel approach that combines an automated breast cancer grading platform with genomics to personalize risk assessment and management. Observation – Origins: The use of histology in determining breast cancer (BCA) clinical risk assignment, including stage, tumor size, and histologic grade, remains an important component of treatment selection and management. Recent studies have shown the value of combining these characteristics with genetic signals such as…

Jia Xu, Ph.D., Instructor – Oncological Sciences at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – LB195 / 8 – AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B.   Observation – The PI3K/AKT/mTOR signaling network is one of the most often dysregulated pathways in cancer development, and the serine/threonine kinase AKT serves as a critical node in this route, regulating various cellular and physiological processes. Clinical trials have shown that AKT inhibitors that competitively bind the…

Jia Xu, Ph.D., Instructor – Oncological Sciences at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – LB195 / 8 – AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B.   Observation – The PI3K/AKT/mTOR signaling network is one of the most often dysregulated pathways in cancer development, and the serine/threonine kinase AKT serves as a critical node in this route, regulating various cellular and physiological processes. Clinical trials have shown that AKT inhibitors that competitively bind the…

Russell Rockne, Ph.D., associate professor, Department of Computational and Quantitative Medicine, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 2732 / 3 – A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy.   Observation –   Origins: Immunotherapy with chimeric antigen receptor – T (CAR-T) cells and targeted radionuclide therapy (TRT) are two promising cancer therapies. These medicines frequently have limited efficacy in completely eradicating cancer cells, making the combination of these two medications an appealing cancer treatment strategy. Because of the difficulties associated in administering and scheduling…

Russell Rockne, Ph.D., associate professor, Department of Computational and Quantitative Medicine, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 2732 / 3 – A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy.   Observation –   Origins: Immunotherapy with chimeric antigen receptor – T (CAR-T) cells and targeted radionuclide therapy (TRT) are two promising cancer therapies. These medicines frequently have limited efficacy in completely eradicating cancer cells, making the combination of these two medications an appealing cancer treatment strategy. Because of the difficulties associated in administering and scheduling…

Neha Vapiwala, MD, FACR, FASTRO, Professor and Vice Chair of Education, Radiation Oncology, Associate Dean of Admissions, Perelman School of Medicine, University of Pennsylvania speaks about The New England Journal of Medicine – Intersectional Analysis of U.S. Medical Faculty Diversity over Four Decades.     Outline According to the 2020 U.S. Census data, the United States’ population is quickly diversifying. We wanted to see if clinical faculty and leadership representation at academic medical schools reflects the changing demographics of the population. Using data from the Association of American Medical Colleges from 1977 to 2019, we discovered significant progress in female…

Neha Vapiwala, MD, FACR, FASTRO, Professor and Vice Chair of Education, Radiation Oncology, Associate Dean of Admissions, Perelman School of Medicine, University of Pennsylvania speaks about The New England Journal of Medicine – Intersectional Analysis of U.S. Medical Faculty Diversity over Four Decades.     Outline According to the 2020 U.S. Census data, the United States’ population is quickly diversifying. We wanted to see if clinical faculty and leadership representation at academic medical schools reflects the changing demographics of the population. Using data from the Association of American Medical Colleges from 1977 to 2019, we discovered significant progress in female…

Mansi Saxena, Ph.D., Associate Facility Director, Vaccine and Cell Therapy Laboratory at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 Abstract – CT108 / 5 – Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to Montanide® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence.   Observation –   Origins:   Dendritic cells (DCs) are essential in the anti-tumor immune response. Tumor-induced immunosuppression, on the other hand, promotes DC dysfunction and T cell exhaustion, culminating…

Mansi Saxena, Ph.D., Associate Facility Director, Vaccine and Cell Therapy Laboratory at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 Abstract – CT108 / 5 – Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to Montanide® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence.   Observation –   Origins:   Dendritic cells (DCs) are essential in the anti-tumor immune response. Tumor-induced immunosuppression, on the other hand, promotes DC dysfunction and T cell exhaustion, culminating…

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. In this video, he speaks about Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.   Observation –   Backstory:   Trastuzumab emtansine is the current standard of care for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose illness has progressed after treatment with an anti-HER2 antibody plus a taxane.   Methodologies:   In patients with HER2-positive metastatic breast cancer…

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. In this video, he speaks about Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.   Observation –   Backstory:   Trastuzumab emtansine is the current standard of care for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose illness has progressed after treatment with an anti-HER2 antibody plus a taxane.   Methodologies:   In patients with HER2-positive metastatic breast cancer…

Jennifer M. Kalish, MD, Ph.D., Assistant Professor of Pediatrics, Research Scientist, Director, Beckwith-Wiedemann Syndrome Clinic, at Children’s Hospital of Philadelphia. In this video, she speaks about the AACR 2022 abstract – 5220 – The consequences of 11p15 mosaicism in Beckwith-Wiedemann syndrome/spectrum: Epigenotypes associated with cancer development and necessity for universal tumor screening.     Beckwith-Wiedemann Spectrum Condition (BWSp) is the most prevalent (epi)genetic cancer predisposition disorder. BWSp has a variable clinical course and is caused by epigenetic alterations at two locations on chromosome 11p15. These epigenetic alterations take place post-zygotically, resulting in a patchwork distribution across tissues. Clinical molecular testing…

Jennifer M. Kalish, MD, Ph.D., Assistant Professor of Pediatrics, Research Scientist, Director, Beckwith-Wiedemann Syndrome Clinic, at Children’s Hospital of Philadelphia. In this video, she speaks about the AACR 2022 abstract – 5220 – The consequences of 11p15 mosaicism in Beckwith-Wiedemann syndrome/spectrum: Epigenotypes associated with cancer development and necessity for universal tumor screening.     Beckwith-Wiedemann Spectrum Condition (BWSp) is the most prevalent (epi)genetic cancer predisposition disorder. BWSp has a variable clinical course and is caused by epigenetic alterations at two locations on chromosome 11p15. These epigenetic alterations take place post-zygotically, resulting in a patchwork distribution across tissues. Clinical molecular testing…

Yuan Yuan, Ph.D., medical oncologist, City of Hope, and Colt Egelston, Ph.D., assistant research professor at the Beckman Research Institute of the City of Hope. In this video, they speak about the AACR 2022 Abstract – 5208 – Circulating T cell: B cell: NK cell axis associated with response to pembrolizumab plus doxorubicin in patients with metastatic triple negative breast cancer.   Outline   In patients with programmed death ligand 1-positive (PD-L1+) metastatic triple negative breast cancer, the use of immune checkpoint inhibitors (ICI) in combination with chemotherapy is now the standard of care (mTNBC). However, the mechanisms of ICI…

Yuan Yuan, Ph.D., medical oncologist, City of Hope, and Colt Egelston, Ph.D., assistant research professor at the Beckman Research Institute of the City of Hope. In this video, they speak about the AACR 2022 Abstract – 5208 – Circulating T cell: B cell: NK cell axis associated with response to pembrolizumab plus doxorubicin in patients with metastatic triple negative breast cancer.   Outline   In patients with programmed death ligand 1-positive (PD-L1+) metastatic triple negative breast cancer, the use of immune checkpoint inhibitors (ICI) in combination with chemotherapy is now the standard of care (mTNBC). However, the mechanisms of ICI…

Mark LaBarge, Ph.D., professor, Department of Population Sciences, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 5682 – Accelerated biological age is a driver of cancer susceptibility in genetic high risk breast tissue.   Outline   Luminal epithelial cells in the human mammary gland lose lineage fidelity as they age by displaying markers normally present in myoepithelial cells. We postulate that loss of lineage fidelity is a common feature of epithelia that is predisposed to cancer initiation. We show that histologically normal breast tissue from younger women who are predisposed to breast cancer due…

Mark LaBarge, Ph.D., professor, Department of Population Sciences, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 5682 – Accelerated biological age is a driver of cancer susceptibility in genetic high risk breast tissue.   Outline   Luminal epithelial cells in the human mammary gland lose lineage fidelity as they age by displaying markers normally present in myoepithelial cells. We postulate that loss of lineage fidelity is a common feature of epithelia that is predisposed to cancer initiation. We show that histologically normal breast tissue from younger women who are predisposed to breast cancer due…

Trey Ideker, Ph.D., UCSD Professor of Medicine, Bioengineering and Computer Science, and former Chief of Genetics. He directs or co-directs the National Resource for Network Biology, and the Cancer Cell Map and Psychiatric Cell Map Initiatives at the University of California, San Diego. In this video, he speaks about the AACR 2022 presentation based on the study – Interpretation of cancer mutations using a multiscale map of protein systems.   Intro:   Tumor genome sequencing has revealed that other than a few typically altered genes, the majority of mutations affecting cancer genomes are uncommon. A powerful technique for interpreting these…

Trey Ideker, Ph.D., UCSD Professor of Medicine, Bioengineering and Computer Science, and former Chief of Genetics. He directs or co-directs the National Resource for Network Biology, and the Cancer Cell Map and Psychiatric Cell Map Initiatives at the University of California, San Diego. In this video, he speaks about the AACR 2022 presentation based on the study – Interpretation of cancer mutations using a multiscale map of protein systems.   Intro:   Tumor genome sequencing has revealed that other than a few typically altered genes, the majority of mutations affecting cancer genomes are uncommon. A powerful technique for interpreting these…

Nada Jabado, MD, Ph.D., Professor of Pediatrics and Human Genetics at McGill University and a staff physician in the Division of Hematology and Oncology at the Montreal Children’s Hospital at McGill University. In this video, she speaks about the AACR 2022 Presentation – Deciphering oncohistone pathogenicity and exquisite vulnerabilities.

Nada Jabado, MD, Ph.D., Professor of Pediatrics and Human Genetics at McGill University and a staff physician in the Division of Hematology and Oncology at the Montreal Children’s Hospital at McGill University. In this video, she speaks about the AACR 2022 Presentation – Deciphering oncohistone pathogenicity and exquisite vulnerabilities.

Mariya Rozenblit, MD, Instructor of Medicine (Medical Oncology) and cares for patients with a clinical focus on breast cancer from Yale School of Medicine. In this video, she speaks about the abstract Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes.   Abstract Goal: Age is one of the most significant risk factors for the development of breast cancer; nevertheless, the underlying etiology between age and breast cancer remains unknown. We previously discovered correlations between epigenetic aging signatures in breast/tumor tissue and breast cancer risk/prevalence. However, these DNA…

Mariya Rozenblit, MD, Instructor of Medicine (Medical Oncology) and cares for patients with a clinical focus on breast cancer from Yale School of Medicine. In this video, she speaks about the abstract Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes.   Abstract Goal: Age is one of the most significant risk factors for the development of breast cancer; nevertheless, the underlying etiology between age and breast cancer remains unknown. We previously discovered correlations between epigenetic aging signatures in breast/tumor tissue and breast cancer risk/prevalence. However, these DNA…

Prof. Dr. Enrique Estrada-Lobato, IAEA Nuclear Medicine Physician. In this video, he speaks about the IAEA’s Support of breast cancer screening along the Amazon River. He also introduces the IAEA’s six decades of experience in helping countries use nuclear techniques to prevent, diagnose and treat cancer. Women in Amazon River villages will have better access to breast cancer screening starting this year, owing to two new mammography devices deployed on Brazilian navy ships delivering crucial health services along South America’s longest waterway. The two devices carried onboard the ships Soares de Meirelles and Carlos Chagas, procured by the International Atomic…

Prof. Dr. Enrique Estrada-Lobato, IAEA Nuclear Medicine Physician. In this video, he speaks about the IAEA’s Support of breast cancer screening along the Amazon River. He also introduces the IAEA’s six decades of experience in helping countries use nuclear techniques to prevent, diagnose and treat cancer. Women in Amazon River villages will have better access to breast cancer screening starting this year, owing to two new mammography devices deployed on Brazilian navy ships delivering crucial health services along South America’s longest waterway. The two devices carried onboard the ships Soares de Meirelles and Carlos Chagas, procured by the International Atomic…

Debu Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. In this video, he speaks about the Miami Breast 2022 discussion – Primer in Genomics: Applications to the Clinic in 2022.

Debu Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. In this video, he speaks about the Miami Breast 2022 discussion – Primer in Genomics: Applications to the Clinic in 2022.

Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr. Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III…

Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial, and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III…

Debiao Li, Ph.D., Director, Biomedical Imaging Research Institute, Professor, Biomedical SciencesProfessor, Imaging, Principal Investigator at Cedars-Sinai, and Stephen Pandol, MD, Director, Basic and Translational Pancreas Research, Program Director, Gastroenterology Fellowship Program at Cedars-Sinai. In this video, they discuss the article AI and machine learning could improve cancer diagnosis through biomarker discovery.    Many industries and fields of study have been changed by artificial intelligence (AI), deep learning (DL), and machine learning (ML). These techniques are now being used to solve the issues of cancer biomarker development, where huge volumes of imaging and molecular data must be analyzed in ways that…

Debiao Li, Ph.D., Director, Biomedical Imaging Research Institute, Professor, Biomedical SciencesProfessor, Imaging, Principal Investigator at Cedars-Sinai, and Stephen Pandol, MD, Director, Basic and Translational Pancreas Research, Program Director, Gastroenterology Fellowship Program at Cedars-Sinai. In this video, they discuss the article AI and machine learning could improve cancer diagnosis through biomarker discovery.    Many industries and fields of study have been changed by artificial intelligence (AI), deep learning (DL), and machine learning (ML). These techniques are now being used to solve the issues of cancer biomarker development, where huge volumes of imaging and molecular data must be analyzed in ways that…

Bradley J. Monk, MD, FACOG, FACS, at GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, Arizona, and global primary investigator of the ATHENA trial. In this video, he speaks about Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival In First-Line Maintenance Treatment In Women With Ovarian Cancer Regardless Of Their Biomarker Status In Phase 3 ATHENA-MONO Trial.   This is a Phase 3 randomized, global, double-blind, dual placebo-controlled, 4-arm research investigating rucaparib plus nivolumab as maintenance treatment in patients with newly diagnosed ovarian cancer who have responded to front-line treatment. The…

Bradley J. Monk, MD, FACOG, FACS, at GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, Arizona and global primary investigator of the ATHENA trial. In this video, he speaks about Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival In First-Line Maintenance Treatment In Women With Ovarian Cancer Regardless Of Their Biomarker Status In Phase 3 ATHENA-MONO Trial.   This is a Phase 3 randomized, global, double-blind, dual placebo-controlled, 4-arm research investigating rucaparib plus nivolumab as maintenance treatment in patients with newly diagnosed ovarian cancer who have responded to front-line treatment. The…

Eric Tkaczyk, MD, Ph.D., FAAD, Director Vanderbilt Dermatology Translational Research Clinic, Staff Physician Department of Veterans Affairs, Nashville Dermatology and Research Services, Assistant Professor Department of Dermatology, Assistant Professor Biomedical Engineering at Vanderbilt University Medical Center and Inga Saknite, Ph.D., Adjoint Assistant Professor of Dermatology, Department of Dermatology, Vanderbilt University Medical Center Senior Researcher, Biophotonics Laboratory, Institute of Atomic Physics and Spectroscopy, University of Latvia. In this video, they speak about a Study Finds 10-Second Videos Predict Blood Cancer Relapse.   A new study from Vanderbilt University Medical Center found that 10-second recordings of white blood cell mobility in the…

Eric Tkaczyk, MD, Ph.D., FAAD, Director Vanderbilt Dermatology Translational Research Clinic, Staff Physician Department of Veterans Affairs, Nashville Dermatology and Research Services, Assistant Professor Department of Dermatology, Assistant Professor Biomedical Engineering at Vanderbilt University Medical Center and Inga Saknite, Ph.D., Adjoint Assistant Professor of Dermatology, Department of Dermatology, Vanderbilt University Medical Center Senior Researcher, Biophotonics Laboratory, Institute of Atomic Physics and Spectroscopy, University of Latvia. In this video, they speak about Noninvasive Videomicroscopy Predicts Blood Cancer Relapse. A new study from Vanderbilt University Medical Center found that 10-second recordings of white blood cell mobility in the skin ‘s microvasculature considerably…

Nicholas John Maragakis, MD, Director, ALS Center for Cell Therapy and Regeneration Research, Professor of Neurology at Johns Hopkins Medicine. In this video, he speaks about Johns Hopkins Researchers Identify a Potential Window for Treating ALS, as well as, some cancers. Amyotrophic lateral sclerosis (ALS) is a neurological condition that affects up to 30,000 people in the United States each year, with 5,000 new cases reported. It gradually weakens muscles, impairing physical function and eventually leading to death. The condition has no single cause and no recognized remedy. However, Johns Hopkins Medicine researchers have discovered a potential window of opportunity…

Nicholas John Maragakis, MD, Director, ALS Center for Cell Therapy and Regeneration Research, Professor of Neurology at Johns Hopkins Medicine. In this video, he speaks about Johns Hopkins Researchers Identify a Potential Window for Treating ALS, as well as, some cancers. Amyotrophic lateral sclerosis (ALS) is a neurological condition that affects up to 30,000 people in the United States each year, with 5,000 new cases reported. It gradually weakens muscles, impairing physical function and eventually leading to death. The condition has no single cause and no recognized remedy. However, Johns Hopkins Medicine researchers have discovered a potential window of opportunity…

Xianxin Hua, MD, Ph.D., Professor of Cancer Biology at the Abramson Cancer Research Institute, Department of Cancer Biology at the University of Pennsylvania Perelman School of Medicine. In this video, he speaks about the Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues.   PHILADELPHIA — Although chimeric antigen receptor (CAR) T cells can be extremely effective in treating leukemias and lymphomas, there are currently no viable immunotherapies for neuroendocrine tumors (NETs) and gastrointestinal malignancies (GICs). Penn Medicine researchers discovered that CAR-T cells directed to a tumor antigen, CDH17, a cell surface…

Xianxin Hua, MD, Ph.D., Professor of Cancer Biology at the Abramson Cancer Research Institute, Department of Cancer Biology at the University of Pennsylvania Perelman School of Medicine. In this video, he speaks about the Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues.   PHILADELPHIA — Although chimeric antigen receptor (CAR) T cells can be extremely effective in treating leukemias and lymphomas, there are currently no viable immunotherapies for neuroendocrine tumors (NETs) and gastrointestinal malignancies (GICs). Penn Medicine researchers discovered that CAR-T cells directed to a tumor antigen, CDH17, a cell surface…

Stephanie Halene, MD, Ph.D., Associate Professor of Medicine (Hematology); Chief, Hematology; Director, DeLuca Center for Innovation in Hematology Research, Yale Cancer Center; Assistant Medical Director CRSL, Yale Cancer Center at Yale University;  Toma Tebaldi, Ph.D., Adjunct Assistant Professor, and Giulia Biancon, Ph.D., Postdoctoral Associate at Yale School of Medicine. In this video, they speak about Yale Scientists Discover a New Pathogenic Mechanism in Hematological Malignancies.   Stephanie Halene, MD, Ph.D., cares for patients with hematologic malignancies and works to bridge the gap between the clinic and the basic science laboratories.   Toma Tebaldi, Ph.D., my research aims at understanding the…

Stephanie Halene, MD, Ph.D., Associate Professor of Medicine (Hematology); Chief, Hematology; Director, DeLuca Center for Innovation in Hematology Research, Yale Cancer Center; Assistant Medical Director CRSL, Yale Cancer Center at Yale University;  Toma Tebaldi, Ph.D., Adjunct Assistant Professor, and Giulia Biancon, Ph.D., Postdoctoral Associate at Yale School of Medicine. In this video, they speak about Yale Scientists Discover a New Pathogenic Mechanism in Hematological Malignancies.   Stephanie Halene, MD, Ph.D., cares for patients with hematologic malignancies and works to bridge the gap between the clinic and the basic science laboratories. Toma Tebaldi, Ph.D., my research aims at understanding the RNA…

Debra Dyer, MD, FACR, Professor, a radiologist at National Jewish Health. Dr. Dyer serves as Chair of the Department of Radiology. In this video, she speaks about New Medicare Lung Cancer Screening Guidelines a Huge Step Forward – More Lives to be Saved. As screening becomes more prevalent, providers should pursue quality assurance. New Centers for Medicare and Medicaid Services (CMS) proposals to reduce the initial age and smoking history requirements for lung cancer screening (LCS) could make these exams the most effective cancer screening tests in history. The American College of Radiology® (ACR®), the GO2 Foundation for Lung Cancer,…

Debra Dyer, MD, FACR, Professor, a radiologist at National Jewish Health. Dr. Dyer serves as Chair of the Department of Radiology. In this video, she speaks about New Medicare Lung Cancer Screening Guidelines a Huge Step Forward – More Lives to be Saved. As screening becomes more prevalent, providers should pursue quality assurance. New Centers for Medicare and Medicaid Services (CMS) proposals to reduce the initial age and smoking history requirements for lung cancer screening (LCS) could make these exams the most effective cancer screening tests in history. The American College of Radiology® (ACR®), the GO2 Foundation for Lung Cancer,…

Charles E. Geyer, Jr., MD, FACP, Principal Investigator for NSABP B-55 Portion of the OlympiA Trial, Medical Oncologist & Breast Cancer Specialist, Chief Scientific Officer, NSABP Foundation Pittsburg Pennsylvania. In this video, he speaks about Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.   Abstract – Origins: Poly(adenosine diphosphate–ribose) polymerase inhibitors use synthetic lethality to target tumors with deficiencies in homologous recombination repair. To minimize recurrence in patients with BRCA1 or BRCA2 germline mutation–associated early breast cancer, new medicines are required.   Methodologies: Patients with human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, BRCA1 or BRCA2…

Charles E. Geyer, Jr., MD, FACP, Principal Investigator for NSABP B-55 Portion of the OlympiA Trial, Medical Oncologist & Breast Cancer Specialist, Chief Scientific Officer, NSABP Foundation Pittsburg Pennsylvania. In this video, he speaks about Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.   Abstract – Origins: Poly(adenosine diphosphate–ribose) polymerase inhibitors use synthetic lethality to target tumors with deficiencies in homologous recombination repair. To minimize recurrence in patients with BRCA1 or BRCA2 germline mutation–associated early breast cancer, new medicines are required.   Methodologies: Patients with human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, BRCA1 or BRCA2…

Julie Wu, MD, Ph.D., Medical Oncology Fellow at Stanford University. In this video, she speaks about the IASLC 2022 Abstract – The Impact of Molecular Driver Mutations on Brain Metastasis Risk Depends on Timing of Brain Metastasis Relative to Diagnosis.   Origins:   Patients with ALK- or EGFR-mutated lung cancer have a higher prevalence of brain metastases (BrM). However, it is unclear if this is attributable to patients’ extended survival, a lack of earlier targeted therapeutic brain penetration, or intrinsic driving biology. Patients who present with BrM at the time of distant metastasis, i.e., synchronous BrM, may be less influenced…

Julie Wu, MD, Ph.D., Medical Oncology Fellow at Stanford University. In this video, she speaks about the IASLC 2022 Abstract – The Impact of Molecular Driver Mutations on Brain Metastasis Risk Depends on Timing of Brain Metastasis Relative to Diagnosis.   Origins:   Patients with ALK- or EGFR-mutated lung cancer have a higher prevalence of brain metastases (BrM). However, it is unclear if this is attributable to patients’ extended survival, a lack of earlier targeted therapeutic brain penetration, or intrinsic driving biology. Patients who present with BrM at the time of distant metastasis, i.e., synchronous BrM, may be less influenced…

Aakash Desai, MD, MPH Hematology-Oncology Fellow at Mayo Clinic. In this video, he speaks about the IASLC 2022 Abstract – Real-World Experience of Lurbinectedin Beyond the Second Line in Small Cell Lung Cancer.   Origins:   Patients with small cell lung cancer (SCLC) have few alternatives for treatment after platinum-based regimens and immunotherapy. The US Food and Drug Administration (FDA) has granted fast approval to lurbinectedin, an alkylating agent, for patients with metastatic SCLC who have progressed on or after traditional frontline therapy.   We describe our institutional experience with lurbinectedin in the third-line context or beyond for SCLC in…

Aakash Desai, MD, MPH Hematology-Oncology Fellow at Mayo Clinic. In this video, he speaks about the IASLC 2022 Abstract – Real-World Experience of Lurbinectedin Beyond the Second Line in Small Cell Lung Cancer.   Origins:   Patients with small cell lung cancer (SCLC) have few alternatives for treatment after platinum-based regimens and immunotherapy. The US Food and Drug Administration (FDA) has granted fast approval to lurbinectedin, an alkylating agent, for patients with metastatic SCLC who have progressed on or after traditional frontline therapy.   We describe our institutional experience with lurbinectedin in the third-line context or beyond for SCLC in…

Eric Collisson, MD, Professor of Medicine at UC San Francisco, and Adam Renslo, Ph.D., Professor, Pharmaceutical Chemistry at UC San Francisco. In this video, they speak about Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.   Overview:   KRAS mutations are responsible for one-quarter of cancer deaths, and the majority are untreatable. Several MAPK pathway inhibitors are FDA-approved, however, they are poorly tolerated at the levels required to effectively suppress RAS/RAF/MAPK signaling in tumor cells. Oncogenic KRAS signaling increased ferrous iron (Fe2+) buildup early in and during mutant KRAS-mediated transformation, we discovered. We were able to establish…

Eric Collisson, MD, Professor of Medicine at UC San Francisco, and Adam Renslo, Ph.D., Professor, Pharmaceutical Chemistry at UC San Francisco. In this video, they speak about Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.   Overview:   KRAS mutations are responsible for one-quarter of cancer deaths, and the majority are untreatable. Several MAPK pathway inhibitors are FDA-approved, however, they are poorly tolerated at the levels required to effectively suppress RAS/RAF/MAPK signaling in tumor cells. Oncogenic KRAS signaling increased ferrous iron (Fe2+) buildup early in and during mutant KRAS-mediated transformation, we discovered. We were able to establish…

Jens Hillengass, MD, Ph.D., Chief of Myeloma, Professor of Oncology at Roswell Park Comprehensive Cancer Center. In this video, he speaks about Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Overview: Symptomatic multiple myeloma is distinguished by osteolytic lesions (OL). The methods by which malignant plasma cells (PC) cause OL in one place while not causing bone damage in others despite thorough invasion remain unexplained. We present a prospective single-cell RNA sequencing (scRNA-seq) investigation of PC derived from random bone marrow aspirates (BM) and matched imaging-guided OL biopsies. Based on the scRNA-seq analysis, we examined 148,630…

Kevin Kalinsky, MD, MS, Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Louisa and Rand Glenn Family Chair in Breast Cancer Research, Director, Glenn Family Breast Center, Director, Breast Medical Oncology at Winship Cancer Institute of Emory University at Emory University. In this video, he speaks about the Miami Breast Abstract – Risk Stratification in Early-Stage Hormone Receptor−Positive Breast Cancer.

Kevin Kalinsky, MD, MS, Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Louisa and Rand Glenn Family Chair in Breast Cancer Research, Director, Glenn Family Breast Center, Director, Breast Medical Oncology at Winship Cancer Institute of Emory University at Emory University. In this video, he speaks about the Miami Breast Abstract – Risk Stratification in Early-Stage Hormone Receptor−Positive Breast Cancer.

Christian Rolfo, MD, Ph.D., MBA, Dr.hc., Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai. In this video, he speaks about an Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.     Outline   Intent:   Entrectinib inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and has previously elicited profound [57.4 percent] and sustained [median duration of response (DoR) 10.4 months] responses in…

Christian Rolfo, MD, Ph.D., MBA, Dr.hc., Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai. In this video, he speaks about an Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.     Outline   Intent:   Entrectinib inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and has previously elicited profound [57.4 percent] and sustained [median duration of response (DoR) 10.4 months] responses in…

Gerard E Mullin, MD, MS, Associate Professor of Medicine at Johns Hopkins Medicine. In this video, he speaks about Study: Taller Adults May be at Increased Risk for Colorectal Cancer.   Outline   Origins:   The impact of anthropometric factors on colorectal neoplasia biology remains unknown. A comprehensive review and meta-analysis were performed to assess whether adult-attained height is independently linked with the risk of colon cancer or adenoma. Methods: From inception through August 2020, we searched MEDLINE, EMBASE, the Cochrane Library, and Web of Science for papers on the relationship between adult-attained height and colorectal cancer or adenoma. The…

Gerard E Mullin, MD, MS, Associate Professor of Medicine at Johns Hopkins Medicine. In this video, he speaks about Study: Taller Adults May be at Increased Risk for Colorectal Cancer.   Outline   Origins:   The impact of anthropometric factors on colorectal neoplasia biology remains unknown. A comprehensive review and meta-analysis were performed to assess whether adult-attained height is independently linked with the risk of colon cancer or adenoma. Methods: From inception through August 2020, we searched MEDLINE, EMBASE, the Cochrane Library, and Web of Science for papers on the relationship between adult-attained height and colorectal cancer or adenoma. The…

Jens Hillengass, MD, Ph.D., Chief of Myeloma, Professor of Oncology at Roswell Park Comprehensive Cancer Center. In this video, he speaks about Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.   Overview:   Symptomatic multiple myeloma is distinguished by osteolytic lesions (OL). The methods by which malignant plasma cells (PC) cause OL in one place while not causing bone damage in others despite thorough invasion remain unexplained. We present a prospective single-cell RNA sequencing (scRNA-seq) investigation of PC derived from random bone marrow aspirates (BM) and matched imaging-guided OL biopsies. Based on scRNA-seq analysis, we examined…

Prof. dr. Xavier Pivot, MD, Ph.D., Professor of Oncology, General Director of Paul Strauss anti-Cancer Center, Chairman of the Regional Cancer Institute at Institute De Cancerologie Stansbourg (iCANS). In this video, he speaks about the Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting.   Overview:   Importance HD201 is a biosimilar candidate to trastuzumab in the treatment of breast cancer.   The goal of this study was to evaluate the efficacy of HD201 to that of the comparator trastuzumab.   Design, environment, and participants:   This randomized clinical trial (TROIKA) recruited…

Prof. dr. Xavier Pivot, MD, Ph.D., Professor of Oncology, General Director of Paul Strauss anti-Cancer Center, Chairman of the Regional Cancer Institute at Institute De Cancerologie Stansbourg (iCANS). In this video, he speaks about the Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting.   Overview:   Importance HD201 is a biosimilar candidate to trastuzumab in the treatment of breast cancer.   The goal of this study was to evaluate the efficacy of HD201 to that of the comparator trastuzumab.   Design, environment, and participants:   This randomized clinical trial (TROIKA) recruited…

Constantinos Koumenis, Ph.D., BS, Richard H. Chamberlain Professor of Research Oncology, Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania. In this video, he speaks about Penn Medicine Awarded $12.3M NIH Grant to Study Ultra-Fast, High-Dose FLASH Radiation Therapy for Cancer.   Description in Detail:   The purpose of this clinical study is to evaluate the workflow feasibility of FLASH radiation treatment in a clinical setting, as well as the toxicities and pain alleviation when utilized to treat bone metastasis(-es) in the extremities (excluding feet, hands, wrists). FLASH radiotherapy has been found in preclinical experiments to cause less…

Constantinos Koumenis, Ph.D., BS, Richard H. Chamberlain Professor of Research Oncology, Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania. In this video, he speaks about Penn Medicine Awarded $12.3M NIH Grant to Study Ultra-Fast, High-Dose FLASH Radiation Therapy for Cancer.   Description in Detail:   The purpose of this clinical study is to evaluate the workflow feasibility of FLASH radiation treatment in a clinical setting, as well as the toxicities and pain alleviation when utilized to treat bone metastasis(-es) in the extremities (excluding feet, hands, wrists). FLASH radiotherapy has been found in preclinical experiments to cause less…

Philippe Bedard, MD is an Associate Professor of Medicine at the University of Toronto. He is a Staff Medical Oncologist in the Division of Medical Oncology and the Fellowship Director for the Bras Drug Development Program at the Princess Margaret Cancer Centre in Toronto. In this video, he speaks about the SABCS 2021 Abstract – Safety and Efficacy of INT230-6, a Potential First-in-Class Intratumoral Therapy, in Monotherapy and in Combination with Pembrolizumab: Results from the IT-01 Study KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Breast Cancer.     Description in detail:   INT230-6 is a fixed-ratio combination of…

Philippe Bedard, MD is an Associate Professor of Medicine at the University of Toronto. He is a Staff Medical Oncologist in the Division of Medical Oncology and the Fellowship Director for the Bras Drug Development Program at the Princess Margaret Cancer Centre in Toronto. In this video, he speaks about the SABCS 2021 Abstract – Safety and Efficacy of INT230-6, a Potential First-in-Class Intratumoral Therapy, in Monotherapy and in Combination with Pembrolizumab: Results from the IT-01 Study KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Breast Cancer.     Description in detail:   INT230-6 is a fixed-ratio combination of…

John H. Bushweller, Ph.D., Professor, Molecular Physiology and Biological Physics at the University of Virginia, Program Leader at UVA Cancer Center. In this video, he speaks about Surprise Discovery Suggests New Treatment for Deadly Lung Cancer.   An unexpected discovery at the University of Virginia Cancer Center has enabled scientists to prevent the progression of small-cell lung cancer in lab mice, and the surprising finding may pave the way for a new therapeutic method in humans.   The researchers, led by UVA’s Kwon-Sik Park and John H. Bushweller, wanted to know how a mutation in the EP300 gene contributes to…

John H. Bushweller, Ph.D., Professor, Molecular Physiology and Biological Physics at the University of Virginia, Program Leader at UVA Cancer Center. In this video, he speaks about Surprise Discovery Suggests New Treatment for Deadly Lung Cancer.   An unexpected discovery at the University of Virginia Cancer Center has enabled scientists to prevent the progression of small-cell lung cancer in lab mice, and the surprising finding may pave the way for a new therapeutic method in humans.   The researchers, led by UVA’s Kwon-Sik Park and John H. Bushweller, wanted to know how a mutation in the EP300 gene contributes to…

M. Michele Blackwood, MD, FACS, Chief, Section of Breast Surgery, Rutgers Cancer Institute of New Jersey, Northern Regional Director of Breast Services, RWJBarnabas Health. In this video, she speaks about the I-SPY2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY).   Description in detail:   I-SPY will compare the efficacy of new medications combined with traditional chemotherapy to the efficacy of standard therapy alone. The goal is to find better treatment regimens for specific subsets based on molecular characteristics (biomarker signatures) of their condition. As with past adaptive trials, regimens that demonstrate a high Bayesian prediction…

M. Michele Blackwood, MD, FACS, Chief, Section of Breast Surgery, Rutgers Cancer Institute of New Jersey, Northern Regional Director of Breast Services, RWJBarnabas Health. In this video, she speaks about the I-SPY2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY).   Description in detail:   I-SPY will compare the efficacy of new medications combined with traditional chemotherapy to the efficacy of standard therapy alone. The goal is to find better treatment regimens for specific subsets based on molecular characteristics (biomarker signatures) of their condition. As with past adaptive trials, regimens that demonstrate a high Bayesian prediction…

Mark Pegram, MD, is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford Cancer Institute. He currently serves as the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). He also serves as the Associate Dean for Clinical Research Quality at the Stanford University School of Medicine and is the Medical Director of the Stanford Clinical Translational Research Unit – a unit specializing in first-in-human phase I clinical trials. In this video, he speaks about the Miami Breast 2022 Discussion – New Frontiers in Breast Cancer: Targeted Therapy, Immunotherapy, and Combinations.

Mark Pegram, MD, is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford Cancer Institute. He currently serves as the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). He also serves as the Associate Dean for Clinical Research Quality at the Stanford University School of Medicine and is the Medical Director of the Stanford Clinical Translational Research Unit – a unit specializing in first-in-human phase I clinical trials. In this video, he speaks about the Miami Breast 2022 Discussion – New Frontiers in Breast Cancer: Targeted Therapy, Immunotherapy, and Combinations.

Mehmet Altan, MD, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. In this video, he speaks about Pulmonary Toxicities of Immunotherapy.   Outline Immune checkpoint inhibitors are a type of immunotherapy that is increasingly being employed in the treatment of a wide range of malignancies. Immune-related adverse events (irAEs) offer a significant issue in cancer treatment. Pneumonitis, the most common lung irAE, can cause severe interruptions in cancer treatment and can be fatal. The purpose of this chapter is to inform readers on the occurrence and clinical features of pneumonitis, as well as to…

Mehmet Altan, MD, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. In this video, he speaks about Pulmonary Toxicities of Immunotherapy.   Outline Immune checkpoint inhibitors are a type of immunotherapy that is increasingly being employed in the treatment of a wide range of malignancies. Immune-related adverse events (irAEs) offer a significant issue in cancer treatment. Pneumonitis, the most common lung irAE, can cause severe interruptions in cancer treatment and can be fatal. The purpose of this chapter is to inform readers on the occurrence and clinical features of pneumonitis, as well as to…

Michael Alvarado, MD, Professor of Surgery, Division of Surgical Oncology, Director, Breast Surgery Oncology Fellowship at University of California San Francisco. In this video, he speaks about the Miami Breast 2022 Discussion – How Has Neoadjuvant Therapy Affected Multidisciplinary Management?

Michael Alvarado, MD, Professor of Surgery, Division of Surgical Oncology, Director, Breast Surgery Oncology Fellowship at University of California San Francisco. In this video, he speaks about the Miami Breast 2022 Discussion – How Has Neoadjuvant Therapy Affected Multidisciplinary Management?

Aditya Bardia, MD, MPH, Director of Breast Cancer Research, Mass General Cancer Center,  Attending Physician, Mass General Cancer Center, Associate Professor in Medicine, Harvard Medical School. In this video, he speaks about the Miami Breast 2022 discussion – Emerging Data on Oral Selective Estrogen Receptor Degraders and Other Novel Hormonal Therapies.

Aditya Bardia, MD, MPH, Director of Breast Cancer Research, Mass General Cancer Center,  Attending Physician, Mass General Cancer Center, Associate Professor in Medicine, Harvard Medical School. In this video, he speaks about the Miami Breast 2022 discussion – Emerging Data on Oral Selective Estrogen Receptor Degraders and Other Novel Hormonal Therapies.

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the Miami Breast 2022 Abstract – Medical Crossfire®: PRO vs CON: Breast IORT Is the Preferred Accelerated Breast Treatment Option.   Brief Synopsis:   Intraoperative radiotherapy (IORT) is a form of accelerated partial breast irradiation (APBI) in which radiation therapy is provided to the breast tissue during a lumpectomy for breast cancer in a single dose. The Xoft device (Axxent, Xoft, San Jose, CA) is an IORT device for breast cancer that…

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the Miami Breast 2022 Abstract – Medical Crossfire®: PRO vs CON: Breast IORT Is the Preferred Accelerated Breast Treatment Option. Brief Synopsis: Intraoperative radiotherapy (IORT) is a form of accelerated partial breast irradiation (APBI) in which radiation therapy is provided to the breast tissue during a lumpectomy for breast cancer in a single dose. The Xoft device (Axxent, Xoft, San Jose, CA) is an IORT device for breast cancer that uses kilovoltage…

Charles Loprinzi, MD, Regis Professor of Breast Cancer Research, Medical Oncologist at Mayo Foundation for Medical Education and Research at Mayo Clinic. In this video, he speaks about Chemotherapy-Induced Neuropathy: Guidelines and More.

Charles Loprinzi, MD, Regis Professor of Breast Cancer Research, Medical Oncologist at Mayo Foundation for Medical Education and Research at Mayo Clinic. In this video, he speaks about Chemotherapy-Induced Neuropathy: Guidelines and More.

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the Miami Breast 2022 Abstract – The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device.   The study is an observational, prospective, parallel-arm device use study. The study will include 50 participants. The SOZO gadget will be used in the study to examine changes in the participants’ body composition following cancer therapy. The SOZO device…

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the Miami Breast 2022 Abstract – The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device.   The study is an observational, prospective, parallel-arm device use study. The study will include 50 participants. The SOZO gadget will be used in the study to examine changes in the participants’ body composition following cancer therapy. The SOZO device…

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), Professor of Surgery (Oncology), Yale University School of Medicine. In this video, she speaks about the discussion at Miami Breast 2022 – How to Get Involved in Clinical Research…and Recognize What Research Is Worthwhile.

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), Professor of Surgery (Oncology), Yale University School of Medicine. In this video, she speaks about the discussion at Miami Breast 2022 – How to Get Involved in Clinical Research…and Recognize What Research Is Worthwhile.

Laurence Albiges, M.D., Ph.D., Vice-Chair Medical Oncology Department at Gustave Roussy. In this video, she speaks about the ASCO GU 2022 abstract – CheckMate -214 (Abstracts #307 & #352): Follow-up results showing meaningful survival benefits with Opdivo plus Yervoy amongst intermediate- and poor-risk RCC patients with sarcomatoid features – a population with poor prognosis and limited therapeutic options – as well as quality of life improvements amongst the all-randomized population.

Laurence Albiges, M.D., Ph.D., Vice-Chair Medical Oncology Department at Gustave Roussy. In this video, she speaks about the ASCO GU 2022 abstract – CheckMate -214 (Abstracts #307 & #352): Follow-up results showing meaningful survival benefits with Opdivo plus Yervoy amongst intermediate- and poor-risk RCC patients with sarcomatoid features – a population with poor prognosis and limited therapeutic options – as well as quality of life improvements amongst the all-randomized population.

Christopher Cann, MD, Clinical Fellow, Division of Hematology/Oncology, Department of Medicine at Vanderbilt University Medical Center. In this video, he speaks about the IASLC 2022 Abstract – Circulating Tumor DNA Dynamics in Relapsed Small Cell Lung Cancer Are Predictive of Progression-Free and Overall Survival.  Origins: Relapsed small cell lung cancer (SCLC) is difficult to treat, with low overall survival and objective response rates (ORR) (OS). ORR is currently predicted to be 25-50 percent for platinum-sensitive illness and 10-20 percent for platinum-resistant disease, resulting in a short progression-free survival (PFS) of 4-5 months and an OS of less than one year…

Christopher Cann, MD, Clinical Fellow, Division of Hematology/Oncology, Department of Medicine at Vanderbilt University Medical Center. In this video, he speaks about the IASLC 2022 Abstract – Circulating Tumor DNA Dynamics in Relapsed Small Cell Lung Cancer Are Predictive of Progression-Free and Overall Survival.  Origins: Relapsed small cell lung cancer (SCLC) is difficult to treat, with low overall survival and objective response rates (ORR) (OS). ORR is currently predicted to be 25-50 percent for platinum-sensitive illness and 10-20 percent for platinum-resistant disease, resulting in a short progression-free survival (PFS) of 4-5 months and an OS of less than one year…

Stefano Luminari, MD, Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine at Unimore Università degli studi di Modena e Reggio Emilia (UNIMORE). In this video, he speaks about FOLL12: Response-Adapted Maintenance Not Supported in Follicular Lymphoma.   Intent   In patients with follicular lymphoma who had responded to induction immunochemotherapy, we compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction strategy.   Approaches   On the basis of metabolic response and molecular assessment of minimal residual illness, we randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to either standard…

Stefano Luminari, MD, Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine at Unimore Università degli studi di Modena e Reggio Emilia (UNIMORE). In this video, he speaks about FOLL12: Response-Adapted Maintenance Not Supported in Follicular Lymphoma.   Intent   In patients with follicular lymphoma who had responded to induction immunochemotherapy, we compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction strategy.   Approaches On the basis of metabolic response and molecular assessment of minimal residual illness, we randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to either standard RM…

Matthew Smeltzer, Ph.D., MStat, Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health at the University of Memphis. Dr. Smeltzer and his co-authors Scagliotti Giorgio, Heather Wakelee, Tetsuya Mitsudomi, and Fred R. Hirsch worked on this trial.  In this video, he speaks about the International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials.   Outline Overview:   We polled investigators and collected aggregate enrollment data for lung cancer trials around the world before and during the worldwide COVID-19 pandemic to investigate the effects on lung cancer trials.  …

Matthew Smeltzer, Ph.D., MStat, Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health at the University of Memphis. Dr. Smeltzer and his co-authors Scagliotti Giorgio, Heather Wakelee, Tetsuya Mitsudomi, and Fred R. Hirsch worked on this trial.  In this video, he speaks about the International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials.   Outline   Overview:   We polled investigators and collected aggregate enrollment data for lung cancer trials around the world before and during the worldwide COVID-19 pandemic to investigate the effects on lung cancer trials.…

Mark Moasser, MD, Professor, Department of Medicine (Hematology/Oncology) at UC San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center. In this video, he speaks about Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers and Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.

Mark Moasser, MD, Professor, Department of Medicine (Hematology/Oncology) at UC San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center. In this video, he speaks about Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers and Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.

Halle Moore, MD, Associate Professor, Department of Medicine, School of Medicine, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center at Cleveland Clinic. In this video, she gives her comments on Abstracts for HER2-low MBCC. Approximately half of all initial breast tumors have low-level HER2 expression (HER2-low), characterized as immunohistochemically 1+ or 2+ and no HER2 gene amplification as assessed by in situ hybridization. This low HER2 expression is a possible new target for antibody-drug conjugates (ADCs), which are currently being researched. Little is known regarding the prevalence and prognostic importance of low HER2-expression in metastatic breast cancer…

Halle Moore, MD, Associate Professor, Department of Medicine, School of Medicine, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center at Cleveland Clinic. In this video, she gives her comments on Abstracts for HER2-low MBCC.   Approximately half of all initial breast tumors have low-level HER2 expression (HER2-low), characterized as immunohistochemically 1+ or 2+ and no HER2 gene amplification as assessed by in situ hybridization. This low HER2 expression is a possible new target for antibody-drug conjugates (ADCs), which are currently being researched. Little is known regarding the prevalence and prognostic importance of low HER2-expression in metastatic breast cancer…

Adam Brufsky, MD, Ph.D., Professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine’s Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women’s Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; the associate director for clinical investigations at UPMC Hillman Cancer Center; and co-director of the Comprehensive Breast Cancer Center at UPMC. In this interview, he comments on HER2-low MBCC.   Approximately half of all initial breast tumors have…

Adam Brufsky, MD, Ph.D., Professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine’s Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women’s Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; the associate director for clinical investigations at UPMC Hillman Cancer Center; and co-director of the Comprehensive Breast Cancer Center at UPMC. In this interview, he comments on HER2-low MBCC. Approximately half of all initial breast tumors have…

Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics Research; Associate Director for Clinical Research, Comprehensive Cancer Center; Medical Director, Judy & Bernard Briskin Center for Clinical Research; Co-director, Gastrointestinal Cancer Program at City of Hope. In this video, he speaks about Colorectal Cancer Awareness Month.